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Pain management is a critical component of neonatal intensive care, not only for 
ethical reasons, but also because the failure to provide adequate analgesia during early 
life has been associated with poor outcomes. Intravenous acetaminophen is an attractive 
option for treatment of neonatal pain; however, there is a lack of consensus regarding 
optimal dosing guidelines, and safety data are limited. A principal safety concern is 
acetaminophen-induced hepatotoxicity, which depends highly on drug metabolism. 
Unfortunately, neonatal pharmacokinetic data for acetaminophen metabolites are scarce. 
The objective of this dissertation was to explore maturational changes in the 
pharmacokinetics of intravenous acetaminophen and its metabolites in neonates. This 
goal was achieved by completion of three major aims that centered on a prospective 
clinical trial. Neonates with a clinical indication for intravenous analgesia received 
multiple doses of intravenous acetaminophen, and pharmacokinetic samples were 
collected throughout a 72-h study period. Aim 1 focused on development and validation 
of a novel high-performance liquid chromatography–tandem mass spectrometry method 
for simultaneous quantification of acetaminophen and the metabolites derived from 
acetaminophen glucuronidation, sulfation, and oxidation. Suitability of the assay was 
demonstrated by analysis of plasma and urine samples from the neonatal pharmacokinetic 
study. In Aim 2, a population pharmacokinetic model was developed from the parent 
drug concentration–time data. In extremely preterm to full-term neonates, body weight   
iv 
was the principal predictor of intravenous acetaminophen pharmacokinetics. External 
evaluation with a dataset from an independent study suggested that these findings should 
be generalizable to other similar patient populations. Aim 3 focused on development of a 
parent–metabolite population pharmacokinetic model using the data obtained from the 
neonatal pharmacokinetic study. As part of model development, an extensive covariate 
analysis was performed to identify patient characteristics that influenced metabolite 
pharmacokinetic parameters, with a particular focus on formation clearance of 
metabolites derived from acetaminophen oxidation. Maturational changes in the fraction 
of acetaminophen undergoing oxidation were small relative to between-subject 
variability. Collectively, these results improve understanding of the factors influencing 
acetaminophen disposition during the neonatal period, and these findings inform 
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 GLOSSARY OF COMMON TERMS 
 
Akaike information criterion: An indicator of the goodness of fit for a model to a set of 
data observations. The Akaike information criterion is equal to the objective function 
value plus twice the number of model parameters. Thus, it is an indicator of model fit that 
includes a penalty for increased model complexity (i.e., more parameters). The number 
itself is not meaningful, but changes in the Akaike information criterion are informative. 
A decrease in Akaike information criterion indicates an improvement in model fit that 
exceeds the complexity penalty. Unlike comparisons of objective function values, 
comparisons of Akaike information criteria have no statistical interpretation. 
Bayesian information criterion: An indicator of the goodness of fit for a model to a set of 
data observations. The Bayesian information criterion is equal to the objective function 
value plus the product of the number of model parameters and the natural log of the 
number of data observations. Thus, it is an indicator of model fit that includes a penalty 
for increased model complexity (i.e., more parameters). The number itself is not 
meaningful, but changes in the Bayesian information criterion are informative. A 
decrease in Bayesian information criterion indicates an improvement in model fit that 
exceeds the complexity penalty. Unlike comparisons of objective function values, 
comparisons of Bayesian information criteria have no statistical interpretation. Model 
discrimination based on Bayesian information criteria tends to be more conservative than 
that based on Akaike information criteria; i.e., it tends to select the simpler model. 
Between-subject variability: A type of random-effect parameter in a population 
pharmacokinetic model. Between-subject variability describes the magnitude of the 
differences in pharmacokinetic parameter values that occur across individuals. In model 
equations, the random effect for an individual on a given pharmacokinetic parameter is 
typically denoted with the Greek letter eta (η), and the between-subject variability for a 
given pharmacokinetic parameter is described by the variance of the eta distribution, 
which is typically denoted as the square of the Greek letter omega (ω2). In the modeling 
software program NONMEM, the omega (Ω) matrix is used to indicate which between-
subject variance parameters should be estimated. 
Conditional weighted residual: A statistic that is used to evaluate nonlinear mixed effects 
models. The calculation of conditional weighted residuals involves standardization of the 
prediction errors (i.e., the difference between predicted and observed concentrations) in 
order to account for the variability in the predictions as well as the correlation between 
multiple prediction errors from the same individual. Conditional weighted residuals 
should be normally distributed with a mean of 0 and a variance of 1. Therefore, most 
conditional weighted residuals are expected to fall between −3 and +3 (i.e., within 
xvi 
3 standard deviations of the observation). 
Covariate: Any variable that is specific to an individual and may explain pharmacokinetic 
variability. Covariates describe predictable sources (fixed effects) of variability. 
Incorporation of a useful covariate into a pharmacokinetic model is expected to reduce 
the amount of unpredictable variability (random effects). Examples of potential 
covariates include body weight, age, sex, and genotype. 
Extremely preterm: Gestational age <28 weeks. 
Fixed effects: Pharmacokinetic model parameters that take on a single value for all 
individuals in a study population. Fixed-effect parameters include structural 
pharmacokinetic parameters, which describe the shape of the typical concentration time 
course in a population, and covariate parameters, which describe pharmacokinetic 
variability that can be predicted by subject characteristics. In model equations, fixed-
effect parameters are typically denoted with the Greek letter theta (θ). 
Full term: Gestational age ≥37 weeks and <42 weeks. 
Gestational age: The time elapsed between the first day of a mother’s last normal 
menstrual period and the day of delivery. Gestational age is usually expressed in 
completed weeks; e.g., a 30-week, 6-day fetus is considered to have a gestational age of 
30 weeks. 
Individual prediction: A pharmacokinetic model prediction that is based on fixed-effect 
parameters and also incorporates the between-subject random effects. 
Infant: A child with a postnatal age <365 days. Infancy includes the neonatal period. 
Neonate: A child with a postnatal age <28 days. 
Nested models: Two models are considered nested, or hierarchical, when one model is a 
subset of the other; i.e., when setting one (or more) parameter(s) in the larger model to 
the null hypothesis value(s) makes the models identical. 
Nonlinear mixed effects modeling: A modeling approach that simultaneously analyzes all 
data for a study population while still accounting for intra-individual observations. 
Nonlinear refers to the fact that the dependent variable (e.g., concentration) is nonlinearly 
related to the independent variable (e.g., time) and model parameters; mixed effects refers 
to the incorporation of fixed and random effects. One of the most popular software 
programs for nonlinear mixed effects modeling is an acronym of the term (NONMEM). 
In the field of pharmacokinetics, this approach is often more specifically described as 
population pharmacokinetic modeling. 
Normalized prediction distribution error: A simulation-based statistic that is used to 
evaluate nonlinear mixed effects models. Normalized prediction distribution errors take 
into account the full predictive distribution of each observation and account for the 
correlation between multiple observations from the same individual. By construction, 
xvii 
normalized prediction distribution errors should be normally distributed with a mean of 0 
and a variance of 1. 
Objective function value: An indicator of the goodness of fit for a model to a set of data 
observations. The number itself is not meaningful, but changes in objective function 
value are informative. A decrease in objection function value indicates an improvement 
in model fit. If two models are nested, the difference in objective function values is 
approximately asymptotically chi-squared distributed with degrees of freedom equal to 
the difference in the number of parameters; e.g., for two competing models that differ by 
one parameter, a difference of >3.84 units in objective function values is considered a 
significant difference in model fit at p < 0.05. 
Pharmacokinetic parameter: Structural parameters that mathematically describe the shape 
of a concentration time course (e.g., clearance and volume of distribution). 
Population prediction: A pharmacokinetic model prediction that is based only on fixed-
effect parameters (i.e., the structural and covariate parameters). 
Postconceptional age: The time elapsed between the day of conception and the day of 
delivery (i.e., conceptional age) plus the time elapsed since birth (i.e., postnatal age). In 
pregnancies resulting from assisted reproductive technologies, a precise conceptional age 
can be determined; in other cases, conceptional age is assumed to be 2 weeks less than 
gestational age. The American Academy of Pediatrics has recommended that 
postconceptional age should not be used in clinical pediatrics, so the term has largely 
fallen out of favor but still appears in some literature. 
Postmenstrual age: The time elapsed between the first day of a mother’s last normal 
menstrual period and birth (i.e., gestational age) plus the time elapsed since birth (i.e., 
postnatal age). Postmenstrual age is usually expressed in weeks; e.g., an infant with a 
gestational age of 32 weeks and a postnatal age of 4 days has a postmenstrual age of 32.6 
weeks. 
Postnatal age: The time elapsed since birth. Also referred to as chronological age. 
Post term: Gestational age ≥42 weeks. 
Preterm: Gestational age <37 weeks. 
Random effects: Pharmacokinetic model parameters that vary across individuals in a 
study population. Random-effect parameters describe unpredictable pharmacokinetic 
variability, for instance, between-subject variability, between-occasion variability, and 
residual unexplained variability. 
Residual unexplained variability: A type of random-effect parameter in a population 
pharmacokinetic model. Residual unexplained variability describes the magnitude of the 
unexplained differences between the predicted and observed concentrations. In model 
equations, the random effect for an observation is typically denoted with the Greek letter 
epsilon (ε), and the residual unexplained variability is described by the variance of the 
xviii 
epsilon distribution, which is typically denoted as the square of the Greek letter sigma 
(σ2). In the modeling software program NONMEM, the sigma (Σ) matrix is used to 
indicate which residual unexplained variance parameters should be estimated. 
Very preterm: Gestational age ≥28 weeks and <32 weeks. 
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Pain Management in Neonates 
Over the course of the 20th century, neonatal mortality in the United States 
decreased substantially [1, 2]. A recent report from the National Center for Health 
Statistics showed that the neonatal mortality rate, which is defined as the number of 
deaths before a postnatal age of 28 days per 1,000 live births, continued to decline from 
2000 to 2011 [3]. Reductions in neonatal mortality rate that have occurred since 1970 
have largely been attributed to advances in medical care [1, 2], but decreases in neonatal 
deaths have been accompanied by increases in the number of critically ill neonates 
requiring intensive care. In the United States, overall admission rates to neonatal 
intensive care units (NICUs) were recently estimated at 77.9 per 1,000 live births, and 
rates ranged from 43.0 per 1,000 live births for normal-birth-weight infants (2.5–4.0 kg) 
to 844.1 per 1,000 live births for very low-birth-weight infants (<1.5 kg) [4]. 
Neonatal intensive care often involves exposure to pain from surgery, disease 
state, or repeated procedures such as endotracheal intubation, heel puncture, indwelling 
arterial and venous catheter insertion, nasogastric tube insertion, and nasal, tracheal, and 
gastric suctioning [5, 6]. Estimates from prospective studies showed that newborns 
underwent a mean of 10–12 painful procedures per day during the first 14 days of NICU 
hospitalization [5, 7]. Consequently, pain management is a critical component of neonatal 
intensive care, not only for humanitarian reasons, but also because the failure to provide 
adequate analgesia during early life has been associated with poor short- and long-term 
outcomes [8]. 
As recently as the 1980s, neonates were assumed to have an inability or 




paradigm-shifting paper by Anand and Hickey helped to establish that pain pathways are 
intact and functional in neonates [9]. In neonates, painful stimuli produce acute 
behavioral and physiological responses. Behavioral responses include crying and specific 
facial expressions and body movements [10-12]; physiological responses are reflected in 
cardiorespiratory, hormonal, and metabolic changes [8, 9, 12]. In neonates who received 
inadequate surgical anesthesia, acute physiological stress responses were accompanied by 
short-term circulatory and metabolic complications [13]. Long-term adverse outcomes 
associated with neonatal pain exposure are numerous and include neuromorphological 
effects [14, 15], growth impairments [16], cognitive and motor deficits [17], and altered 
pain thresholds [12]. Collectively, these findings highlight the importance of achieving 
effective neonatal analgesia. 
 
Intravenous Acetaminophen 
In neonates, acetaminophen (N-acetyl-p-aminophenol, paracetamol) is commonly 
used for treatment of mild to moderate procedural pain or as part of multimodal 
postoperative pain management [8, 18]. Acetaminophen was first synthesized in 1888 
and has been widely used since it was first marketed to consumers in the mid-20th century 
[19]. Today, acetaminophen is one of the most commonly used medications in the United 
States, and the prevalence of use is high in both adults [20-22] and children [23]. It has 
been estimated that 26% of children <2 years of age use a product containing the drug 
each week [23]. Acetaminophen is used for its analgesic and antipyretic effects, which 
are thought to occur primarily via inhibition of cyclooxygenase activity and prostaglandin 




ductus arteriosus in preterm neonates has also piqued interest in a new potential 
indication [25]. 
Oral and rectal formulations of acetaminophen have long been available, but 
intravenous formulations are relatively new. The first intravenous formulation, 
propacetamol, is a prodrug that is rapidly hydrolyzed by plasma esterases to produce 
acetaminophen. Propacetamol has not been approved by the United States Food and Drug 
Administration but it is available in other countries. Unfortunately, propacetamol requires 
reconstitution and is associated with infusion-site discomfort [26, 27]. More recently, an 
intravenous formulation of the active drug was developed in a ready-to-use solution that 
elicits few infusion-site reactions [27, 28]. Intravenous acetaminophen was first approved 
in 2002 in Europe and is marketed under the trade name Perfalgan [29]. In the United 
States, intravenous acetaminophen was approved in 2010, and the formulation is 
marketed under the trade name Ofirmev [30]. Intravenous acetaminophen has been 
rapidly adopted into clinical practice and has been described as “a worthy addition to the 
analgesic armamentarium” [31]. The intravenous formulations allow for administration of 
the drug in situations when enteral delivery is unsuitable, for instance, during 
postoperative periods. Additionally, intravenous delivery provides predictable 
bioavailability and onset of action compared to enteral routes [32, 33]. 
In the United States, intravenous acetaminophen is only approved for use in adults 
and in children 2 years of age or older; it is indicated for management of mild to 
moderate pain, management of moderate to severe pain with adjunctive opioid 
analgesics, and fever reduction [30]. In other countries, intravenous acetaminophen is 




intravenous acetaminophen to neonates occurs worldwide [18]. Intravenous 
acetaminophen is a particularly attractive option for neonatal analgesia because it has 
fewer side effects and is generally better tolerated than opioids [8, 34], and postoperative 
use of intravenous acetaminophen in neonates has been shown to reduce morphine 
requirements [35]. The licensed dose for patients weighing 10 kg or less, including term 
neonates, is 7.5 mg/kg every 4–6 h, with a maximum daily dose of 30 mg/kg [29]. In 
practice, diverse dosing regimens have been implemented [36-38]. Many of these 
regimens comprise higher-than-licensed doses, which have been suggested by neonatal 
pharmacokinetic studies (Table 1.1) [18, 36-39]. In the clinical trial that is the focus of 
this dissertation, 15-mg/kg doses were administered at 12-h intervals to neonates <28 
weeks’ gestation (30 mg/kg/day) and at 8-h intervals to neonates ≥28 weeks’ gestation 
(45 mg/kg/day), and these total daily doses are roughly consistent with many of the 
suggested dosing regimens listed in Table 1.1. 
 
Pharmacokinetics of Intravenous Acetaminophen in Neonates 
Appropriate dose selection for neonates is complicated by developmental changes 
that occur during early life [40]. Acetaminophen is primarily eliminated by hepatic 
metabolism, so measures of hepatic maturation and function are critical for explanation 
of between-subject variability in acetaminophen pharmacokinetics [39, 41-44]. A number 
of recent neonatal studies have reported on the pharmacokinetics of intravenous 
acetaminophen [39, 42] and propacetamol [45-47]; however, there is still a lack of 
consensus regarding optimal dosing guidelines (Table 1.1) [18, 36-39]. Furthermore, 







Table 1.1 Suggested neonatal dosing regimens for intravenous acetaminophen. 
 







[29] Licensed dose for Perfalgan Term neonates 
 Loading: n/s 
 Maintenance: 7.5 4–6 30
a 
[36] “Stockholm protocol” 
28–32 wks PCA  Loading: 20  Maintenance: 7.5 8 22.5–35 
33–36 wks PCA  Loading: 20  Maintenance: 7.5 6 30–42.5 
>37 wks PCA  Loading: 20  Maintenance: 10–15 6 40–65 
[37] Allegaert  et al. 2007 
<31 wks PCA  Loading: 20  Maintenance: 10 12 20–30 
31–36 wks PCA  Loading: 20  Maintenance: 10 8 30–40 
>36 wks PCA  Loading: 20  Maintenance: 10 6 40–50 
[48] Neonatal formulary 
<30 wks PMA  Loading: 20  Maintenance: 10 6 40–50 
31–36 wks PMA  Loading: 20  Maintenance: 12.5 6 50–57.5 
Term neonates  Loading: 20  Maintenance: 15 6 60–65 
[18] Dutch formulary 
<31 wks PMA  Loading: 20  Maintenance: 10 n/s 20
b 
31–36 wks PMA  Loading: 20  Maintenance: 10 n/s 30
b 
Term neonates  Loading: 20  Maintenance: 10 n/s 40
b 
[39] Allegaert  et al. 2011 32–44 wks PMA 
 Loading: 20 
 Maintenance: 10 6 40–50 
 
a Maximum daily dose limited to 30 mg/kg. 
b Maximum amount from maintenance dosing per day. 




scarce [18, 39, 42]. The age-based breakpoints in the dosing regimens listed in Table 1.1 
are somewhat arbitrary but reflect the tendency of clinicians to recommend more 
conservative drug administration for less mature neonates. 
Estimates for clearance of intravenous acetaminophen in neonates range from 
0.090–0.21 L/h/kg, depending in part upon gestational, postmenstrual, or 
postconceptional age [39, 42, 45-47]. The distribution of intravenous acetaminophen in 
neonates has been described with both one- [45-47] and two-compartment [39, 42] 
pharmacokinetic models, and volume of distribution estimates range from 0.56–0.76 L/kg 
[42, 46]. Neonatal pharmacokinetic parameter estimates can be extrapolated to a standard 
70-kg adult using allometric scaling exponents of 0.75 and 1 for clearance and volume of 
distribution, respectively [49]. Allometrically standardized estimates from neonatal 
studies of intravenous acetaminophen range from 70–76 L/70 kg for volume of 
distribution [39, 45, 47] and 2.9–7.1 L/h/70 kg for clearance. These standardized neonatal 
volumes of distribution are consistent with the typical adult range of 0.7–1.0 L/kg [50]. 
The standardized neonatal clearance values are approximately 20–40% of typical adult 
values [51], and this relatively low neonatal clearance can be attributed to incomplete 
maturation of hepatic drug metabolism pathways [44, 52-54]. Zuppa et al. have described 
the pharmacokinetics of intravenous acetaminophen across the pediatric age range and 
found that standardized clearance values increased from birth and plateaued near adult 
values by approximately 2 years of age [41]. The study by Zuppa et al. only included 
three full-term neonates; nevertheless, the findings are consistent with the studies that 
focused solely on neonatal subjects. 




characteristic (covariate) influencing intravenous acetaminophen pharmacokinetics in 
neonates [39, 45, 47]. Postmenstrual age [39, 47], postconceptional age [45], and 
unconjugated bilirubin [39, 47] have also been shown to have minor effects on neonatal 
clearance of intravenous acetaminophen. More specifically, high unconjugated bilirubin 
has been associated with reduced clearance [39, 47], and correlation in concentrations of 
acetaminophen and unconjugated bilirubin might derive from the fact that both molecules 
undergo substantial clearance via glucuronidation. 
Perhaps the most comprehensive study to date on the pharmacokinetics of 
intravenous acetaminophen in neonates is the pooled analysis performed by Allegaert et 
al. [39]. After identifying body weight as the principal predictor of intravenous 
acetaminophen pharmacokinetics in neonates with postmenstrual ages of 32–44 weeks, 
the authors proposed a parsimonious dosing regimen in which maturational changes in 
acetaminophen pharmacokinetics could be accommodated using only equivalent per-
kilogram dosing, without requirements for different doses or dosing intervals dependent 
upon gestational or postmenstrual age [39]. The appropriateness of implementing such a 
dosing regimen in neonates of <32 weeks’ postmenstrual age requires further 
investigation. Additionally, the efficacy of the proposed dosing regimen should be 
evaluated in pharmacodynamic studies. Finally, appropriate dosing should also be guided 
by safety data. The principal safety concern that accompanies use of acetaminophen is the 







Acetaminophen Metabolism and Acetaminophen-Induced 
Hepatotoxicity 
When used as indicated, acetaminophen is well tolerated [24, 55, 56]. At 
supratherapeutic doses, however, the drug has long been known to produce liver necrosis 
[57-60], and acetaminophen overdose is currently the leading cause of acute liver failure 
in the United States [61]. Drug metabolism plays a key role in acetaminophen-induced 
hepatotoxicity, as illustrated in Figure 1.1 [62, 63]. Much of the present understanding of 
the relationship between acetaminophen metabolism and hepatotoxicity stems from 
research performed in the National Institutes of Health laboratory of James Gillette and 
B. B. Brodie. The results of their rodent model experiments were published in 1973 in a 
series of seminal papers by Mitchell et al. [64, 65], Jollow et al. [66], and Potter et al. 
[67]. 
Acetaminophen metabolism occurs primarily in the liver, where the drug 
undergoes glucuronidation and sulfation by UDP-glucuronosyltransferases (UGTs) and 
sulfotransferases (SULTs), respectively. The nontoxic glucuronide and sulfate 
metabolites are efficiently excreted in the urine. Acetaminophen can also be oxidized by 
hepatic cytochrome P450 enzymes (CYPs) to form the reactive intermediate N-acetyl-p-
benzoquinone imine (NAPQI). At therapeutic doses, only a small portion (5–15%) of 
acetaminophen is bioactivated to yield NAPQI. This electrophilic species can be 
detoxified by conjugation with glutathione, either nonenzymatically or with the aid of 
glutathione S-transferase enzymes. The acetaminophen-glutathione conjugate undergoes 
rapid hydrolysis by hepatic gamma-glutamyl transpeptidase and dipeptidases to form 






























acetyltransferases, thus producing acetaminophen-N-acetylcysteine [68, 69]. Given a 
sufficiently high dose of acetaminophen, the glutathione detoxification pathway can be 
saturated by NAPQI, and excess electrophile will instead bind covalently to hepatic 
proteins [62, 63]. Toxicity is thought to result from a combination of inactivation of 
critical hepatic proteins via NAPQI binding and oxidative stress [70, 71]. 
As illustrated in Figure 1.1, the balance between different metabolic pathways 
plays a critical role in influencing susceptibility to acetaminophen-induced 
hepatotoxicity. Furthermore, this balance can be influenced by individual characteristics 
(e.g., genetics, ethnicity, sex, age) as well as extrinsic factors (e.g., nutritional status, 
concomitant drug/xenobiotic exposure, circadian variation, repeated acetaminophen 
exposure). Ample evidence from rodent model studies illustrates the interplay between 
factors affecting acetaminophen metabolism and acetaminophen-induced hepatotoxicity, 
including age [72], sex [73], natural products exposure [74], fasting [75], diurnal 
variation [76], and repeated acetaminophen exposure [77]. In humans, it is difficult to 
obtain proof of causal relationships between metabolic effects of such factors and 
susceptibility to acetaminophen-induced hepatotoxicity; however, some associations have 
been noted. Court et al. found that a single nucleotide polymorphism in the UGT1A-3ʹ 
untranslated region (rs8330) was associated with enhanced in vitro acetaminophen 
glucuronidation, and also showed that this polymorphism was underrepresented in 
patients with acute liver failure following unintentional acetaminophen overdose 
compared to acute liver failure from other causes (intentional acetaminophen overdose or 
non-acetaminophen-induced acute liver failure) [78]. There is also evidence that acute 




hepatotoxicity via inhibition of CYP2E1 and, conversely, that chronic alcohol exposure 
increases the risk of toxicity via induction of CYP2E1 expression, although the 
relationship between alcohol exposure and acetaminophen-induced hepatotoxicity is 
somewhat contentious [24, 62]. 
 
Acetaminophen Metabolism in Neonates 
Children are generally thought to be more resistant to acetaminophen-induced 
hepatotoxicity than adults [79-81], but hepatic safety data for intravenous acetaminophen 
in neonates are quite limited. One retrospective study based on data collected from 
preterm neonates, term neonates, and young infants showed no significant increase in 
serum alanine aminotransferase, aspartate aminotransferase, or gamma-glutamyl 
transpeptidase during or up to 2 days after repeated administration of intravenous 
acetaminophen [82]. These observations were made during implementation of a dosing 
regimen that was more aggressive than the licensed schedule (see [37] in Table 1.1), and 
they suggest that such dosing is well tolerated. However, the analysis was only based on 
serum liver enzyme measurements, which suffer from well-documented limitations [83]. 
Additionally, these findings are based on retrospective data from a single study center. 
As discussed in the previous section, inter-individual differences in 
acetaminophen metabolism are likely to influence susceptibility to acetaminophen-
induced hepatotoxicity. Furthermore, substantial developmental changes in drug 
metabolism occur during the neonatal period [84, 85], and maturational differences might 
increase the risk of acetaminophen-induced hepatotoxicity in certain subgroups of 




remain scarce across all routes of administration, and previous studies that have 
incorporated metabolite data focused on the glucuronide and sulfate conjugates [42, 52, 
53, 86-88]. 
Both early [52, 53] and recent [42, 86-88] studies on the neonatal 
pharmacokinetics of acetaminophen-sulfate and acetaminophen-glucuronide have 
generally relied on urinary excretion data. In neonates, sulfation is the predominant route 
of acetaminophen elimination [42, 52, 53, 86-88]. Glucuronidation accounts for the 
majority of acetaminophen clearance in adults, but glucuronidation capacity is immature 
in neonates [44, 89]. Van der Marel et al. modeled the pharmacokinetics of 
acetaminophen and its glucuronide and sulfate metabolites in infants and young children 
with an age range of approximately 5–20 months [90]. Weight-standardized formation 
(hepatic) clearance of acetaminophen-sulfate did not increase with age, but 
acetaminophen-glucuronide formation clearance increased with age from an extrapolated 
neonatal value of 2.7 L/h/70 kg to 6.6 L/h/70 kg at 20 months of age, which is 
approximately half of adult estimates. 
Neonatal pharmacokinetic data for acetaminophen-sulfate and acetaminophen-
glucuronide agree reasonably well with data from ontogenic expression and activity 
studies. In a panel of human fetal and postnatal liver cytosol preparations, acetaminophen 
sulfation exhibited a strong negative correlation with estimated gestational age during the 
earlier stages of development (10–25 weeks’ estimated gestational age), but activity was 
relatively stable from an estimated gestational age of approximately 25 weeks through 
adolescence [91]. Results from experiments with human liver microsomes and 




acetaminophen glucuronidation [92]. A role for UGT2B15 in acetaminophen 
glucuronidation has also been supported by in vivo data [93]. In fetal liver samples (20 
weeks’ gestation), mRNA expression for these four UGT isoforms was undetectable [94]. 
By 6 months after birth, transcript levels for UGT1A1, UGT1A6, and UGT2B15 reached 
adult values, and by 7 months after birth, protein expression of UGT1A1 and UGT1A6 
was also consistent with that in adults. For UGT1A9, mRNA expression was detectable 
at 6 months of age but did not approach adult values until 1.5 years after birth. In vitro 
activity for glucuronidation of bilirubin, a UGT1A1-specific substrate, are consistent with 
these mRNA and protein expression data: as a percentage of adult activity, bilirubin 
glucuronidation was 0.1% at 17–30 weeks’ gestation and 1% at 30–40 weeks’ gestation; 
a rapid age-dependent increase has been observed after birth, independent of gestational 
age, and adult activity values were reached by 8–15 weeks’ postnatal age [89, 95-97].  
Neonatal pharmacokinetic data for CYP-derived metabolites (acetaminophen-
cysteine and acetaminophen-N-acetylcysteine) are lacking, but some information on the 
ontogeny of relevant CYP enzymes is available from expression and activity studies. In 
humans, CYP2E1 is primarily responsible for the oxidation of acetaminophen to NAPQI 
[62]. Vieira et al. were unable to detect CYP2E1 protein or enzyme activity in human 
fetal liver at >30 weeks’ gestation but observed that both protein content and activity 
increased dramatically on the first day after birth, regardless of gestational age [98]. 
Protein expression and enzyme activity then followed similar, steady increases over the 
course of infancy, and values for 1–10 year olds approached those of adults. 
Measurements of hepatic CYP2E1 protein expression obtained by Johnsrud et al. were 




detectable in many fetal liver samples obtained at >20 weeks’ gestation. CYP2E1 protein 
content increased most markedly during the first few months after birth and approached 
adult values by about 90 days’ postnatal age [99]. Birth was not always associated with a 
spike in CYP2E1 protein expression, and this inconsistency in the onset of expression 
contributed to substantial between-subject variability in neonatal samples (80-fold 
variation). Nevertheless, in a subset of samples from subjects with known gestational and 
postnatal ages, postnatal age was strongly correlated with CYP2E1 content (p < 0.001) 
and gestational age was not (p = 0.07). This observation is compatible with the notion 
that peripartum or postnatal factors play a significant role in initiating CYP2E1 protein 
expression, which is in line with the findings of Vieira et al. 
Collectively, results from relevant enzyme ontogeny studies highlight the volatile 
and variable nature of neonatal drug metabolism, and these findings underscore the need 
for further studies of acetaminophen metabolism in this vulnerable patient population. 
 
Utility of Population Pharmacokinetic Modeling  
for Neonatal Studies 
Pediatric pharmacokinetic studies pose numerous challenges in terms of both 
physiological factors and study design considerations [100]. Physiologically, children 
exhibit substantial differences in the pharmacokinetic processes of absorption, 
distribution, metabolism, and excretion compared to adults. Furthermore, both inter- and 
intra-subject variability in these processes are often large because of substantial 
developmental changes that occur during early life [40, 101]. Historically, limitations on 




populations. For instance, based on neonatal volume restrictions, an overall maximum of 
9 mL of blood may be collected over a 4-week period. These figures contrast sharply 
with acceptable collection volumes for adults, from whom such a volume could easily be 
collected in a matter of hours [100]. Fortunately, the exquisite sensitivity and specificity 
of modern analytical techniques has enabled quantification of drugs and metabolites in 
ever-decreasing sample volumes [102]. The introduction of population-based modeling to 
pediatric pharmacokinetic analysis in the 1980s has also proved critical to surmounting 
many challenges associated with pediatric study design. 
Traditional pharmacokinetic analysis involves estimation of pharmacokinetic 
parameters for each individual in a study population based on individual concentration–
time profiles. Individual pharmacokinetic parameters are then summarized with measures 
of central tendency, such as means or medians, and measures of variability, such as 
standard errors or interquartile ranges. In the traditional approach, a relatively large 
number of samples must be collected from each patient and the sample collection times 
must be quite consistent across individuals. Additionally, this statistical approach tends to 
overestimate the amount of between-subject variability in pharmacokinetic parameters 
because it has a poor ability to differentiate between between-subject and within-subject 
variability [103].  
In contrast to traditional pharmacokinetic analysis, population pharmacokinetic 
modeling occurs simultaneously for an entire population but still accounts for intra-
individual observations [104, 105]. The population approach is more generally referred to 
as nonlinear mixed effects modeling. Nonlinear refers to the fact that the dependent 




and model parameters; mixed effects refers to the incorporation of fixed and random 
effects. Fixed-effect parameters take on a single value for all individuals in a study 
population and include the structural pharmacokinetic parameters, which describe the 
shape of the typical concentration time course in a population, and the covariate 
parameters, which describe pharmacokinetic variability that is predictable based on 
subject characteristics. Random-effect parameters vary across individuals in a study 
population and describe unpredictable pharmacokinetic variability, including between-
subject variability and within-subject variability (e.g., residual unexplained variability). 
Importantly, population-based modeling allows for analysis of pharmacokinetic data that 
is both sparse (i.e., few samples per subject) and unbalanced (i.e., collected at 
inconsistent points on the concentration–time curve across individuals). Such data is 
typical of pediatric trials because of ethical and logistical constraints on sample 
collection. The ability to incorporate systematic covariate analyses for identification of 
influential patient characteristics is another feature that is particularly useful for studies in 
neonates, who often exhibit substantial pharmacokinetic variability due to a complex 
interplay between maturational processes. 
 
Research Objective and Major Findings by Chapter 
The overarching objective of this dissertation was to explore maturational changes 
in the pharmacokinetics of intravenous acetaminophen and its metabolites in neonates. 
This goal was achieved by completion of three major aims (Chapters 2–4) that were 
centered on a prospective clinical trial. The study was approved by the Institutional 




conducted in accordance with good clinical practice. In brief, neonates with a clinical 
indication for intravenous analgesia received acetaminophen (15 mg/kg/dose) for 5 doses 
at 12-h intervals (<28 weeks’ gestation) or for 7 doses at 8-h intervals (≥28 weeks’ 
gestation). The breakpoint in dosing protocol at 28 weeks’ gestation was somewhat 
arbitrary but is in line with other published regimens (Table 1.1), which generally 
incorporate more conservative dosing practices for less mature neonates. Plasma and 
urine samples were collected throughout a 72-h pharmacokinetic study period. 
Importantly, there was good representation of extremely preterm, preterm, and term 
neonates among the study subjects. 
 
Chapter 2 
In recent years, a number of liquid chromatography–tandem mass spectrometry 
methods have been published for the sensitive and specific quantification of 
acetaminophen and its metabolites in various human and rodent matrices [106-111]; 
however, most of these included only the parent drug and one or two metabolites as 
analytes [107-110]. One recently reported assay included acetaminophen and the 
glucuronide, sulfate, glutathione, cysteine, and N-acetylcysteine conjugates, but the 
method required two 16-min analytical injections per sample, one for each ionization 
mode, in order to achieve adequate sensitivity. Additionally, the assay was validated for 
analysis of rat plasma, not human matrices [106]. 
Chapter 2 focuses on the development and validation of methods for simultaneous 
quantification of acetaminophen, acetaminophen-glucuronide, acetaminophen-sulfate, 




cysteine in human plasma and urine by high-performance liquid chromatography–
electrospray ionization–tandem mass spectrometry. Details of the methods are provided 
along with comprehensive validation results. Because study sample volumes from the 
neonatal pharmacokinetic trial were extremely limited, the sensitivity of the assays was 
optimized in order to minimize the amount of sample required for each assay. The utility 
and suitability of the assays are illustrated by a brief summary of the pharmacokinetic 




Chapter 3 focuses on the development of a population pharmacokinetic model 
using the parent drug concentration–time data obtained from the neonatal 
pharmacokinetic study. Nonlinear mixed effects models were constructed in NONMEM 
7.2. Potential covariates included body weight, gestational age, postnatal age, 
postmenstrual age, sex, race, total bilirubin, and estimated glomerular filtration rate. An 
external dataset was used to test the predictive performance of the model through 
calculation of bias and precision. In neonates ranging from extremely preterm to full-term 
gestational ages, body weight was the principal predictor of intravenous acetaminophen 
pharmacokinetics. Data were well described by a one-compartment model with first-
order elimination. Clearance and volume of distribution were estimated as 0.348 L/h 
(5.5% relative standard error; 30.8% between-subject variability) and 2.46 L (3.5% 
relative standard error; 14.3% between-subject variability), respectively, at the mean 




generalizable to other similar patient populations. The median prediction error was 10.1% 
(95% confidence interval: 6.1–14.3%) and the median absolute prediction error was 




Chapter 4 focuses on the development of a parent–metabolite population 
pharmacokinetic model using the data obtained from the neonatal pharmacokinetic study. 
Concentration–time data for acetaminophen, acetaminophen-glucuronide, 
acetaminophen-sulfate, and the combined oxidative pathway metabolites 
(acetaminophen-cysteine and acetaminophen-N-acetylcysteine) were simultaneously 
modeled in NONMEM 7.2. As part of the model development process, an extensive 
covariate analysis was performed to identify patient characteristics that influenced 
metabolite pharmacokinetic parameters, with a particular focus on formation clearance of 
the oxidative pathway metabolites. Formation clearances for all metabolites increased 
with weight, and formation clearances for glucuronidation and oxidation also increased 
with postnatal age. At the mean weight (2.3 kg) and postnatal age (7.5 days), formation 
clearance estimates (bootstrap 95% confidence interval; between-subject variability) were 
0.049 L/h (0.038–0.062; 62%) for glucuronidation, 0.21 L/h (0.17–0.24; 33%) for 
sulfation, and 0.058 L/h (0.044–0.078; 72%) for oxidation. Expression of individual 
oxidation formation clearance estimates as a fraction of total individual acetaminophen 
clearance estimates showed that, on average, fractional formation clearance for oxidation 




changes in the fraction of drug undergoing oxidation were small relative to between-
subject variability. This work was not published prior to submission of the final version 
of this dissertation. 
 
Appendix 
One potential limitation of the parent–metabolite model described in Chapter 4 is 
its failure to account for NAPQI that covalently binds proteins to form acetaminophen 
protein adducts. Although this fraction of NAPQI is expected to be small relative to the 
amount conjugated by glutathione, future studies could explore this point more 
thoroughly by measuring acetaminophen protein adducts in neonatal study samples and 
testing for covariate effects on the pharmacokinetics of circulating acetaminophen protein 
adducts. The material in this appendix has been included with such an application in 
mind. A novel procedure is reported for quantification of a biomarker of acetaminophen 
protein adducts in human serum by high-performance liquid chromatography–
electrospray ionization–tandem mass spectrometry. Details of the method are provided 
along with validation results. The utility of the assay is illustrated by a brief summary of 
the analysis of serum samples collected from human subjects taking chronic, therapeutic 
doses of acetaminophen. This work has been published in the Journal of 
Chromatography B [113]. 
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SIMULTANEOUS QUANTIFICATION OF ACETAMINOPHEN 
AND FIVE ACETAMINOPHEN METABOLITES IN HUMAN 
PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY–ELECTROSPRAY IONIZATION–
TANDEM MASS SPECTROMETRY: METHOD  
VALIDATION AND APPLICATION TO A  







Drug metabolism plays a key role in acetaminophen (APAP)-induced 
hepatotoxicity, and quantification of APAP metabolites provides critical information 
about factors influencing susceptibility to APAP-induced hepatotoxicity in clinical and 
experimental settings. The aims of this study were to develop, validate, and apply high-
performance liquid chromatography–electrospray ionization–tandem mass spectrometry 
(HPLC–ESI–MS/MS) methods for simultaneous quantification of APAP, APAP-
glucuronide, APAP-sulfate, APAP-glutathione, APAP-cysteine, and APAP-N-
acetylcysteine in small volumes of human plasma and urine. In the reported procedures, 
APAP-d4 and APAP-d3-sulfate were utilized as internal standards (IS). Analytes and IS 
were recovered from human plasma (10 µL) by protein precipitation with acetonitrile. 
Human urine (10 µL) was prepared by fortification with IS followed only by sample 
dilution. Calibration concentration ranges were tailored to literature values for each 
analyte in each biological matrix. Prepared samples from plasma and urine were analyzed 
under the same HPLC–ESI–MS/MS conditions, and chromatographic separation was 
achieved through use of an Agilent Poroshell 120 EC–C18 column with a 20-min run 
time per injected sample. The analytes could be accurately and precisely quantified over 
2.0–3.5 orders of magnitude. Across both matrices, mean intra- and inter-assay 
accuracies ranged from 85–112%, and intra- and inter-assay imprecision did not exceed 
15%. Validation experiments included tests for specificity, recovery and ionization 
efficiency, inter-individual variability in matrix effects, stock solution stability, and 
sample stability under a variety of storage and handling conditions (room temperature, 




procedures were illustrated by analysis of pharmacokinetic samples collected from 
neonates receiving intravenous APAP. 
 
Introduction 
Acetaminophen (APAP) has been widely used for nearly a century and is 
currently one of the most commonly used medications in the United States [1-4]. APAP 
is an effective and well-tolerated analgesic and antipyretic agent when used as indicated 
[5-7]. At supratherapeutic doses, however, the drug has long been known to produce liver 
injury [8-11], and APAP overdose is currently the leading cause of acute liver failure in 
the United States [12]. Consequently, APAP is frequently utilized as a model 
hepatotoxicant [13-15], and studies of the precise mechanistic pathways that ultimately 
result in APAP-induced liver injury are still underway [16, 17]. 
Drug metabolism plays a key role in APAP-induced hepatotoxicity (Figure 2.1) 
[18, 19]. APAP metabolism occurs primarily in the liver, where the drug undergoes 
glucuronidation and sulfation by UDP-glucuronosyltransferases and sulfotransferases, 
respectively. The nontoxic glucuronide (APAP-gluc) and sulfate (APAP-sulf) metabolites 
are efficiently excreted in the urine. APAP can also be oxidized by hepatic cytochrome 
P450 enzymes to form the reactive intermediate N-acetyl-p-benzoquinone imine 
(NAPQI). At therapeutic doses, only a small portion (5–15%) of APAP is bioactivated to 
yield NAPQI. This electrophilic species can be detoxified by conjugation with 
glutathione, either nonenzymatically or with the aid of glutathione S-transferase enzymes. 
The APAP-glutathione conjugate (APAP-glut) undergoes rapid hydrolysis by hepatic 





























and APAP-cys is subsequently acetylated by N-acetyltransferases, thus producing APAP-
N-acetylcysteine (APAP-NAC) [20, 21]. Given a sufficiently high dose of APAP, the 
glutathione detoxification pathway can be saturated by NAPQI, and excess electrophile 
will instead bind covalently to hepatic proteins [18, 19]. Toxicity is thought to result from 
a combination of inactivation of critical hepatic proteins via NAPQI binding and 
oxidative stress [13, 16]. 
Susceptibility to APAP-induced hepatotoxicity is likely to be influenced by 
variability in the major APAP metabolic pathways. Therefore, in both clinical and 
experimental settings, quantification of the major APAP metabolites is essential to 
achieve a thorough understanding of factors affecting hepatotoxicity risk. In recent years, 
a number of liquid chromatography–tandem mass spectrometry (LC–MS/MS) methods 
have been published for the sensitive and specific quantification of APAP and 
metabolites in various human and rodent matrices [22-27]; however, most of these 
included only the parent drug and one or two metabolites as analytes [23-26]. One 
recently reported assay included APAP, APAP-gluc, APAP-sulf, APAP-glut, APAP-cys, 
and APAP-NAC, but the method required two 16-min analytical injections per sample, 
one for each ionization mode, in order to achieve adequate sensitivity. Additionally, the 
assay was validated for analysis of rat plasma, not human matrices [22]. 
We sought to develop and validate methods for simultaneous quantification of 
APAP, APAP-gluc, APAP-sulf, APAP-glut, APAP-cys, and APAP-NAC in human 
plasma and urine by high-performance liquid chromatography–electrospray ionization–
tandem mass spectrometry (HPLC–ESI–MS/MS). Furthermore, we aimed to optimize the 




sample volume minimization was particularly important because the assays were 
intended for use in a neonatal pharmacokinetic study, an application where sample 
volumes are extremely limited. 
Herein we report novel procedures for simultaneous quantification of APAP and 
five APAP metabolites in human plasma and urine by HPLC–ESI–MS/MS. Details of the 
methods are provided along with comprehensive validation results. The utility and 
suitability of the assays are illustrated by a brief summary of the analysis of 
pharmacokinetic plasma and urine samples collected from neonates receiving intravenous 
APAP. 
 
Materials and Methods 
Materials 
Analyte-free human plasma (sodium heparin; from individual donors) was 
obtained from BioChemed Services (Winchester, VA). Analyte-free human urine was 
obtained from APAP-abstinent volunteers at the Center for Human Toxicology (CHT) in 
the Department of Pharmacology and Toxicology at the University of Utah. Human urine 
for matrix stability experiments was obtained from a volunteer at the CHT approximately 
3 h after ingestion of 1 g of APAP (500-mg caplets, Kroger, Cincinnati, OH). The 
following reference standards and deuterated internal standards were obtained from 
Toronto Research Chemicals (Toronto, ON, Canada): acetaminophen (98%), 4-
acetamidophenyl β-D-glucuronide sodium salt (98%), 4-acetaminophen sulfate potassium 
salt (98%), acetaminophen glutathione disodium salt (95%), 3-cysteinylacetaminophen 




(95%), acetaminophen-d4 (APAP-d4, 98% chemical purity, 99% isotopic purity), and 4-
acetaminophen-d3 sulfate (APAP-d3-sulf, 98% chemical purity, 99% isotopic purity). 
APAP (analytical standard) and ammonium acetate (≥98%) were obtained from Sigma–
Aldrich (St. Louis, MO). Glacial acetic acid was obtained from Spectrum Chemicals 
(New Brunswick, NJ). Formic acid (88%) was obtained from Fisher Scientific 
(Pittsburgh, PA). LC–MS grade acetonitrile and methanol were obtained from Honeywell 
Burdick and Jackson (Morristown, NJ). Ultrapure water (18.2 MΩ) for preparation of 
aqueous solutions was obtained by passage of deionized water through a Milli-Q 
Gradient A10 filtration system equipped with a Q-Gard 2 purification pack (EMD 
Millipore, Billerica, MA). Silanized glassware was prepared by vapor-phase silanization 
with hexamethyldisilazane (Pierce, Rockford, IL) under vacuum in an oven at 250°C for 
2 h. 
 
Authentic clinical samples for assay verification 
Clinical samples were collected from subjects enrolled in an Institutional Review 
Board-approved study (Children’s National Health System, Washington, DC) in which 
APAP (Ofirmev, 10 mg/mL, Mallinckrodt Pharmaceuticals, Dublin, Ireland) was 
administered by 30-min intravenous infusions at 15 mg/kg/dose to neonates with a 
clinical indication for intravenous analgesia. Patients <28 weeks gestation received 5 
doses at 12-h intervals; patients ≥28 weeks gestation received 7 doses at 8-h intervals. 
Pharmacokinetic samples were collected prior to the first APAP dose and throughout the 
3-day study period, up to 24 h after the final dose. Blood samples (0.2 mL) were obtained 




Franklin Lakes, NJ). Blood samples were centrifuged at 4°C for 10–15 min at 1500 x g. 
Plasma supernatants were transferred to cryovials and stored at −70°C. Urine samples 
were collected from gel-free study diapers (Cuddle Buns Preemie diapers, Small 
Beginnings Inc., Hesperia, CA) and stored at −70°C. Batches of de-identified study 
samples were shipped overnight on dry ice to the CHT at the University of Utah and 
immediately stored at −80°C until the time of preparation for analysis. 
 
Calibrator, quality control (QC), and  
internal standard (IS) solutions 
Individual stock solutions of analyte reference standards and IS were prepared at 
concentrations ranging from 0.1 to 1 mg/mL in methanol/water (1/1, v/v) using a Mettler 
Toledo XS3DU microbalance (Columbus, OH) and silanized class-A volumetric flasks. 
For reference standards obtained in salt form, all specified concentrations reflect the 
concentration of free analyte. Individual stock solutions were then pooled and diluted to 
prepare a combined working solution with 100 µg/mL APAP, APAP-gluc, and APAP-
sulf and 10.0 µg/mL APAP-glut, APAP-cys, and APAP-NAC in methanol/water (1/1, 
v/v). Lower concentration working solutions were subsequently prepared by 5 10-fold 
serial dilutions in methanol/water (1/1, v/v). Separate sets of analyte stock and working 
solutions were prepared for calibrator and QC applications. APAP reference material 
used for each set was obtained from two different chemical manufacturers. Metabolite 
reference standards of sufficient purity were generally not available from different 
manufacturers or lot numbers; however, calibrator and QC solution sets were prepared by 




prepare IS working solutions with the concentrations indicated below. All stock and 
working solutions were stored at −20°C in silanized glass tubes. 
 
Sample preparation 
Calibrator and QC samples. Prior to use for preparation of calibrator or QC 
samples, individual lots of biological matrix were prepared without IS, analyzed, and 
confirmed to be negative for all analytes and IS. Calibration standards and triplicate sets 
of QC samples were freshly prepared in silanized glass tubes for concurrent analysis with 
each validation or study sample batch. Analyte- and IS-free matrix (10 µL plasma or 
urine) was fortified with analyte working solutions to yield the nominal matrix 
concentrations provided in Table 2.1. Two additional analyte-free matrix samples 
accompanied each batch for preparation with and without IS. 
Plasma sample preparation. Study samples were thawed at ambient temperature 
and gently mixed by vortexing before transfer of 10-µL aliquots to silanized glass tubes. 
To maintain equivalence in preparation and control for the addition of solvent that 
occurred during fortification of calibrator and QC samples with analyte working solution, 
methanol/water (1/1, v/v) was used to bring all samples to a total volume of 110 µL. 
Samples were then fortified with 10 µL of IS working solution containing 0.20 and 25 
µg/mL of APAP-d4 and APAP-d3-sulf, respectively, in water. Acetonitrile (600 µL) was 
added, and each sample was vortex mixed for 30 s before 15 min of centrifugation at 
1100 x g, ambient temperature in an IEC FL40 swing-out rotor centrifuge (Thermo Fisher 
Scientific Inc., Waltham, MA). Sample supernatants were transferred to a clean set of 


























0.050, 0.10, 0.25,  
0.75, 1.0, 2.5,  
7.5, 10, 50 
0.15 0.80 8.0 40 
APAP-glut plasma 
0.0050a, 0.010a, 0.025,  
0.075, 0.10, 0.25,  
0.75, 1.0, 5.0 





0.0050a, 0.010, 0.025,  
0.075, 0.10, 0.25,  
0.75, 1.0, 5.0 





0.0050a, 0.010, 0.025,  
0.075, 0.10, 0.25,  
0.75, 1.0, 5.0b 





0.20, 1.0, 5.0, 10,  
40, 70, 100, 400,  
700, 1,000 
7.5 50 500 n/a 
APAP-gluc 
APAP-sulf urine 
0.20a, 1.0, 5.0, 10,  
40, 70, 100, 400,  
700, 1,000 





0.020a, 0.10, 0.50, 1.0,  
4.0, 7.0, 10, 40,  
70, 100 
0.75 5.0 50 n/a 
 
a Concentration present but excluded from analysis due to failure to meet LLOQ 
acceptance criteria. 
 
b Concentration present but excluded from analysis due to nonlinearity. 
 
c Concentration present but excluded from analysis; concentration falls outside 
calibration range. 
 




15 psi air stream in a TurboVap LV Evaporator (Zymark). Sample residues were 
reconstituted in 400 µL of 0.1% aqueous formic acid, vortex mixed for 30 s, and 
centrifuged for 5 min at 1100 x g, ambient temperature in the swing-out rotor centrifuge. 
From the top of each centrifuged sample, 200 µL was carefully removed and transferred 
to a conical polypropylene autosampler vial. 
Urine sample preparation. Study samples were thawed at ambient temperature 
and gently mixed by vortexing before transfer of 10-µL aliquots to silanized glass tubes. 
To maintain equivalence in preparation and control for the addition of solvent that 
occurred during fortification of calibrator and QC samples with analyte working solution, 
methanol/water (1/1, v/v) was used to bring all samples to a total volume of 110 µL. 
Samples were then fortified with 10 µL of IS working solution containing 10 and 100 
µg/mL of APAP-d4 and APAP-d3-sulf, respectively, in water. Samples were diluted by 
addition of 380 µL of 0.1% aqueous formic acid followed by 20 s vortex mixing. To 
remove any solid particles that might be present, samples were centrifuged for 5 min at 
1100 x g, ambient temperature in the swing-out rotor centrifuge. Sample supernatants 
(100 µL) were carefully transferred to a clean set of silanized glass tubes and diluted in 
an additional 300 µL of 0.1% aqueous formic acid. Following 20 s vortex mixing, 200 µL 
of each sample was transferred to a conical polypropylene autosampler vial. 
 
HPLC–ESI–MS/MS analysis 
HPLC–ESI–MS/MS was conducted on an Agilent 1260 Infinity HPLC system 
(inline solvent micro-degasser, binary LC pump, high-performance thermostatted 




Agilent 6460 triple-quadrupole mass spectrometer (Agilent Technologies, Santa Clara, 
CA). MassHunter Workstation software (Agilent Technologies, Santa Clara, CA) was 
used for instrument control, data acquisition, and ESI–MS/MS parameter optimization 
(version B.03.01) and for data analysis (version B.04.00). 
Prepared samples were stored in the autosampler tray at 5°C. Sample injection 
volumes ranged from 10–100 µL. Injection volumes within each batch did not vary, but 
adjustments were made over time as needed based on changes in instrument response 
(magnitude of chromatographic peak areas). Samples were injected in the following 
order: calibration standards (ascending concentrations), analyte-free samples with and 
without IS, QC set 1, approximately half of the validation/study samples, QC set 2, 
remaining validation/study samples, QC set 3. Between injections, the autosampler 
needle was washed with methanol/water (1/1, v/v). For the plasma assay only, the 
analytical system was equilibrated by injecting 7 extra prepared matrix samples at the 
beginning of each batch. Chromatographic separation was achieved with an Agilent 
Poroshell 120 EC–C18 column (2.1 x 100 mm, 2.7 µm particle size, Agilent 
Technologies, Santa Clara, CA) maintained at 40°C and using a gradient mobile phase 
consisting of 10 mM aqueous ammonium acetate, pH 3.5 (A) and methanol (B) at a flow 
rate of 0.25 mL/min. Mobile phase was maintained at 3% B for the first 6 min, increased 
linearly to 35% B over 3 min, maintained at 95% B for 3 min, decreased linearly to 3% B 
over 0.5 min, and then re-equilibrated at 3% B for 7.5 min, yielding a total run time of 20 
min/injection. The MS diverter valve was only directed to the ion source during the 
anticipated retention time range for analytes and IS. 




multiple reaction monitoring (MRM). APAP-sulf and APAP-d3-sulf were monitored in 
negative ionization mode; all other analytes and APAP-d4 were monitored in positive 
ionization mode. Ultra-high-purity nitrogen was used for source and collision cell gas. 
The following settings were applied: 350°C gas temperature, 10 L/min gas flow, 30 psi 
nebulizer pressure, 350°C sheath gas temperature, 9 L/min sheath gas flow, 3500 V 
capillary voltage, 500 V nozzle voltage, and 250 V delta EMV. Analyte- and IS-specific 
MRM transitions, fragmentor voltages, collision energies, and dwell times are provided 
in Table 2.2. Wide resolution (FWHM approximately 1.2 amu) was applied in both mass 
analyzers. 
 
Quantitation calculations and acceptance criteria 
Throughout method validation and study sample analysis, calibration curves were 
constructed by plotting the analyte/IS chromatographic peak area ratio against the 
nominal analyte concentration in each calibration standard. APAP-d4 was used as the IS 
for APAP, and APAP-d3-sulf was used as the IS for all other analytes. Calibration curves 
were fit by linear regression for all analytes except APAP-gluc, for which a quadratic 
regression was used. Weighting of 1/x2 was applied to all calibration curves. Back-
calculated calibrator and QC concentrations determined by interpolation were required to 
be within ±20% of nominal concentration. Calibration standards that failed to meet this 
criterion were excluded from regression, and at least ¾ of the calibrators were required to 
be included in regression. The lower limit of quantification (LLOQ) was defined as the 
lowest concentration of analyte with acceptable imprecision (≤20%) and mean accuracy 











Table 2.2 Analyte- and IS-specific ESI–MS/MS parameters. 
 

















APAP-gluc 2 + 328.1→152.1 100 5 200 quant 
APAP-d3-sulf 
3 − 233.1→153.1 110 14 200 quant 
3 − 233.1→107.1 110 30 200 qual 
APAP-sulf 
3 − 230.1→150.1 110 14 200 quant 
3 − 230.1→107.1 110 30 200 qual 
APAP-cys 
4 + 271.1→140.0 80 22 100 quant 
4 + 271.1→182.0 80 10 100 qual 
APAP-d4 4 + 156.1→114.1 80 14 100 quant 
APAP 4 + 152.1→110.0 80 14 100 quant 
APAP-glut 5 + 457.1→140.0 110 42 100 quant 
APAP-NAC 
6 + 313.1→208.0 80 14 100 quant 
6 + 313.1→140.0 80 34 100 qual 
 











were required to meet the ±20% accuracy criterion in order for a sample batch to meet 
acceptance criteria for reporting of quantitative results. 
 
Method validation 
The methods were validated by assessment of LLOQ, intra- and inter-day 
accuracy and imprecision, specificity, recovery and ionization efficiency, matrix effect, 
stock solution stability, and sample stability. 
To identify an appropriate LLOQ for each analyte in each matrix, analyte-free 
human plasma and urine were fortified with analyte working solutions at several 
concentrations near the target LLOQ (n = 6 for each concentration). Fortified samples 
were prepared and analyzed, and each appropriate LLOQ was selected based on the 
acceptance criteria described above. A LLOQ calibrator was included in each calibration 
curve, but the LLOQ test replicates were excluded from regression for determinations of 
accuracy and imprecision. 
Accuracy and imprecision were determined from replicate samples of analyte-free 
human plasma and urine fortified with analytes at the QC concentrations indicated in 
Table 2.1. Intra-assay accuracy and imprecision at each concentration were determined 
from 5 replicate samples assayed within the same analytical batch. Inter-assay accuracy 
and imprecision at each concentration were calculated from a total of 20 replicates 
assayed over 7 separate analytical batches. Accuracy is expressed as a percent of the 
nominal concentration and imprecision as percent coefficient of variation (% CV). 
Specificity of the methods was assessed by analysis of human plasma and urine 




peaks co-eluting with either analytes or IS, plasma and urine samples were prepared in 
triplicate according to the usual procedures, and one plasma and urine sample from each 
individual was prepared similarly but without IS fortification. For samples prepared with 
IS, the specificity acceptance criterion for each lot was that the mean analyte/IS peak area 
ratio at the analyte retention time must be <20% of the corresponding peak area ratio 
from a concurrently assayed LLOQ sample. Additionally, qualification transitions were 
incorporated for some analytes (APAP-sulf, APAP-cys, and APAP-NAC), and the 
presence of a qualifier ion peak with a signal-to-noise ratio >3 was required for 
declaration of a positive result for these analytes. For samples prepared without IS, any 
peak area at the IS retention time was required to be <5% of the IS peak area in the 
LLOQ sample in order to meet acceptance criterion. 
Recovery and ionization efficiency (suppression/enhancement) were determined 
at the QC concentrations indicated in Table 2.1. For each biological matrix, one QC set 
(set A, n = 5) was prepared according to the usual procedures. Another QC set (set B, n = 
5) was prepared similarly but IS was added during the final step of sample preparation. A 
third QC set (set C, n = 5) was prepared with water in place of analyte-free matrix and 
with IS added during the final step of sample preparation. In the HPLC–ESI–MS/MS 
injection sequence, each QC set was interspersed so that comparable samples were 
injected consecutively (i.e., low QC A replicate 1, low QC B replicate 1, low QC C 
replicate 1, etc.). IS recovery was calculated by dividing each IS peak area from set A by 
the IS peak area from the corresponding set B sample. Ionization efficiency was 
calculated by dividing each analyte or IS peak area from set B by the analyte or IS peak 




The influence of inter-individual variability in matrix effects on analyte accuracy 
and imprecision was assessed using analyte-free plasma or urine obtained from 6 
individuals. Each lot was fortified with analytes at low and high QC concentrations (QC 
levels 2 and 4 for plasma, and levels 1 and 3 for urine). The fortified samples were then 
prepared for analysis. 
Stability of analyte stock solutions was assessed by comparison of freshly 
prepared solutions to solutions that had been stored at −20°C for approximately 6 or 12 
months. Solutions were diluted in 0.1% aqueous formic acid to concentrations 
appropriate for injection on the HPLC–ESI–MS/MS (n = 3 for each comparison), and the 
test solutions were then analyzed under the usual conditions. Stability was calculated by 
dividing the mean analyte/IS peak area ratios from test solutions prepared from stored 
stocks by the mean analyte/IS peak area ratios from test solutions prepared from the fresh 
stocks. 
 For plasma stability experiments, analyte concentrations were equivalent to the 
lowest and highest QC concentrations. Plasma fortification was performed in triplicate in 
silanized glass tubes by first evaporating appropriate amounts of analyte working 
solutions to dryness in a TurboVap LV Evaporator (35°C water bath, 10–15 psi air 
stream) and then reconstituting each sample in 1 mL analyte-free plasma. Because 
reference standard material is costly and the urine stability samples required relatively 
high analyte concentrations, a urine sample for stability studies was obtained from a 
volunteer at the Center for Human Toxicology who was known to have ingested 1 g of 
APAP approximately 3 h prior. This specimen was serially diluted in analyte-free urine 




regions of the calibration curves. Stability samples were prepared for initial analysis 
immediately after fortification/collection, and aliquots of matrix (200 µL for plasma; 1 
mL for urine) were also subjected to the following conditions: up to 24 h of storage at 
room temperature, up to 6 months (plasma) or 1 month (urine) of storage at −80°C, and 3 
cycles of freezing (at least 12 h storage at −80°C) and thawing (60 min at room 
temperature). Analyte concentrations determined from stored aliquots were then 
compared to the concentrations determined from initial analysis. Additionally, stability of 
prepared samples was assessed following storage in the autosampler (5°C) for 72 h. 
 
Statistical software 
All calculations for descriptive statistics were performed in Excel (version 14.0, 
Microsoft Corp., Redmond, WA). 
 
Results and Discussion 
Method development 
Table 2.1 provides a summary of the calibrator and QC concentrations used for 
both the plasma and urine assays. Based on previous knowledge about APAP 
pharmacokinetics [28], calibration curve ranges were carefully selected to be most 
appropriate for each biological matrix and analyte. Because cytochrome P450-mediated 
oxidation accounts for a small portion of APAP metabolism, plasma concentrations of 
NAPQI-derived metabolites (APAP-glut, APAP-cys, and APAP-NAC) are anticipated to 
be substantially lower than plasma concentrations of the other analytes in samples 




are generally expected to be significantly higher than the respective plasma 
concentrations. Calibrator concentrations for plasma and urine were also designed to be 
compatible with a single set of stock and working solutions so that costly metabolite 
reference standards could be used as economically as possible. As a result, the calibration 
range for APAP in urine extends to much higher concentrations than typically necessary. 
A variety of LC conditions were tested during method development. In addition to 
the Poroshell 120 EC–C18 column, which was ultimately employed for the assay, a 
Polaris C18–A column (2.0 x 150 mm, 5 µm particle size, Agilent Technologies, Santa 
Clara, CA) was considered. Potential aqueous mobile phase solutions included various 
ammonium acetate buffers, formate buffers, dilute formic acid, dilute acetic acid, and 
dilute trifluoroacetic acid. Acetonitrile was also explored as a potential organic mobile 
phase solvent. Additionally, numerous variations in pump flow rate, pump timetable 
program, and column temperature were tested. Ultimately, the conditions reported in the 
Materials and Methods section (above) were found to provide optimal chromatographic 
separation within a reasonable run time. Typical retention times for analytes and IS can 
be observed in Figures 2.2 and 2.3. 
Analyte- and IS-specific ESI–MS/MS parameters are summarized in Table 2.2. 
Ion source and MS/MS conditions were optimized during direct infusion of individual 
analyte solutions (10 µg/mL in methanol/water (1/1, v/v)) at 10 µL/min into 0.25 mL/min 
mobile phase flow with a composition approximately equivalent to that at the time of 
analyte elution from the HPLC column. MRM transitions for analyte quantification were 
selected based on the ability to provide acceptable specificity and optimal product ion 












Figure 2.2 Representative MRM chromatograms for determination of APAP and 
metabolites in human plasma: a analyte- and IS-free plasma, b plasma fortified with IS 
and with APAP and metabolites at each LLOQ. Specific precursor→product ion 
transitions for each analyte and IS are provided in Table 2.2. Solid lines depict MRM 
traces for quantifier transitions and dashed lines depict MRM traces for qualifier 
transitions. Nominal concentrations for analytes and IS are provided in the heading of 
each MRM trace. MRM chromatograms in b are derived from three sample injections 












Figure 2.3 Representative MRM chromatograms for determination of APAP and 
metabolites in human urine: a analyte- and IS-free urine, b urine fortified with IS and 
with APAP and metabolites at each LLOQ. Specific precursor→product ion transitions 
for each analyte and IS are provided in Table 2.2. Solid lines depict MRM traces for 
quantifier transitions and dashed lines depict MRM traces for qualifier transitions. 
Nominal concentrations for analytes and IS are provided in the heading of each MRM 





APAP-NAC, additional qualification transitions were monitored to enhance assay 
specificity. Samples were required to have a qualifier ion peak with a signal-to-noise ratio 
>3 in order for a quantifiable analyte concentration to be reported, and this was 
particularly helpful for samples with concentrations near the LLOQ. Many of these 
quantifier and qualifier mass transitions have previously been utilized in LC–MS/MS 
methods for these analytes [22-24, 26, 29, 30]. 
At the time of initial method development, deuterated analogues of sufficient 
purity for use as IS (≥95%) were unavailable for some analytes. During preliminary 
testing, APAP-d4 performed well as an IS for APAP. However, the instrument response 
was much greater for APAP and APAP-d4 than for the other analytes. This is apparent by 
examination of the peak areas in Figures 2.2b and 2.3b; even when concentration and 
molecular weight differences are taken into account, peak areas for APAP are 
significantly larger than for the other analytes. As a result, APAP-d4 did not perform well 
as an IS for the other analytes. Both APAP and APAP-d4 showed evidence of ion 
suppression at the high end of the calibration curve. This self-induced ion suppression 
was not problematic for quantification of APAP, but it did limit the utility of APAP-d4 as 
an IS for other analytes. Preliminary testing showed that APAP-d3-sulf performed well as 
an IS for APAP-sulf and for the remaining analytes. It provided consistent peak areas 
across the calibration curve ranges and allowed for linear curve fits for all analytes except 
APAP-gluc, for which a quadratic curve fit was applied. IS working solution 
concentrations of APAP-d4 and APAP-d3-sulf were selected based on the relative 
instrument response for each. 




nonpolar parent drug and several highly polar metabolites), nonspecific sample 
preparation procedures were expected to be most suitable. Thus, plasma samples were 
prepared for analysis by protein precipitation, and the relatively high urinary analyte 
concentrations inspired the testing and eventual implementation of a dilution-only urine 
sample preparation. As evidenced by the validation results, these simple and efficient 
preparation procedures performed well. 
 
Method validation 
Appropriate LLOQ concentrations were determined based on the predefined 
acceptance criteria. LLOQ values for the plasma and urine assays are presented in Tables 
2.3 and 2.4, respectively, along with intra-assay accuracy and imprecision data for each 
LLOQ. Representative MRM chromatograms are provided for analyte- and IS-free 
plasma (Figure 2.2a), plasma LLOQ calibrators fortified with IS (Figure 2.2b), analyte- 
and IS-free urine (Figure 2.3a), and urine LLOQ calibrators fortified with IS (Figure 
2.3b). 
Most calibration curves were fit well by linear regression with 1/x2 weighting. 
APAP-gluc, however, required quadratic regression. Also, in plasma, the APAP-NAC 
curve was linear only up to 1.0 µg/mL. Back-calculation of calibrator and QC 
concentrations by interpolation consistently yielded values within ±20% of nominal 
concentration, and coefficients of determination (R2) for calibration curves were typically 
≥0.99. No evidence of chromatographic carryover was observed when analyte-free matrix 
samples were injected immediately after the highest calibration standards. 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































are summarized in Tables 2.3 and 2.4 for plasma and urine, respectively. The methods 
were found to be highly accurate and precise. Mean values for intra- and inter-assay 
accuracy in plasma ranged from 85–112% and 90–108%, respectively. In plasma, intra- 
and inter-assay imprecision did not exceed 14% and 15%, respectively. Mean values for 
intra- and inter-assay accuracy in urine ranged from 87–107% and 92–111%, 
respectively. In urine, intra- and inter-assay imprecision did not exceed 8% and 13%, 
respectively. 
Analysis of human plasma and urine from 6 APAP-abstinent individuals 
demonstrated that the assays provide requisite specificity. In plasma samples fortified 
with IS, mean peak area ratios (analyte/IS) for each lot were <5% of the LLOQ peak area 
ratio for all analytes. Similarly, in plasma samples that were not fortified with IS, peak 
areas in the IS MRM transitions were <0.1% of the IS peak areas in the LLOQ samples. 
In urine samples fortified with IS, mean peak area ratios for APAP-cys/IS were slightly 
greater than 20% in most of the test lots (range: 20–24%); however, these samples did not 
produce detectable peaks in the APAP-cys qualifier MRM transition. For all other 
analytes, mean peak area ratios (analyte/IS) for each urine lot were <19% of the LLOQ 
peak area ratio. In urine samples that were not fortified with IS, peak areas in the IS 
MRM transitions were <1% of the IS peak areas in the LLOQ samples. 
APAP-d4 and APAP-d3-sulf were recovered from plasma at 86 ± 6% and 81 ± 
7%, respectively (mean % recovery ± SD, n = 20). These values suggest that small but 
consistent amounts of IS and, presumably, analytes were lost during the supernatant 
transfer step that occurred prior to sample evaporation. Results for ionization efficiency 




APAP and APAP-sulf, mean ionization efficiencies ranged from 87–97%, suggesting 
insignificant influence of plasma matrix components on analyte ionization. Results for 
APAP-gluc, APAP-glut, and APAP-NAC were indicative of ion suppression, with mean 
ionization efficiencies ranging from 32–75%. In contrast, results for APAP-cys suggest 
that ion enhancement occurred at lower analyte concentrations, with mean ionization 
efficiencies of 381% and 168% at QC levels 1 and 2, respectively. In spite of these 
variable ionization efficiencies, results from the matrix effect experiment demonstrate 
that the influence of plasma matrix components on analyte ionization was relatively 
consistent across 6 different individuals. With the exception of APAP-glut, mean 
accuracies ranged from 101–114% and standard deviations did not exceed 6%. Matrix 
effect results for APAP-glut were less accurate and less precise (Table 2.5); however, 
APAP-glut is arguably the least important of the analytes in this matrix (see further 
discussion below), and these results were therefore considered acceptable for this 
particular analyte. 
APAP-d4 and APAP-d3-sulf were recovered from urine at 104 ± 8% and 104 ± 
7%, respectively (mean % recovery ± SD, n = 15). As expected for a dilution-only 
sample preparation, these values are close to 100%. Results for ionization efficiency and 
matrix effect experiments for the urine assay are summarized in Table 2.6. Across all 
analytes, mean ionization efficiencies ranged from 94–104%, which suggests that urine 
matrix components neither suppressed nor enhanced analyte ionization. Results from the 
matrix effect experiment demonstrate that the analytes could be quantified with 
acceptable accuracy and imprecision in urine from 6 different individuals. Across all 










Table 2.5 Ionization efficiency and matrix effect for determination of APAP and 
metabolites in human plasma. 
 
Compound 
Ionization efficiency (%)a (n = 5) 
Accuracy and 
imprecision of matrix 
effect samples (%)a  













APAP 96 ± 6 93 ± 3 97 ± 5 97 ± 2 101 ± 3 108 ± 1 
APAP-d4 95 ± 10 97 ± 3 96 ± 5 98 ± 6 n/a n/a 
APAP-gluc 32 ± 4 32 ± 1 42 ± 1 51 ± 2 111 ± 6 109 ± 5 
APAP-sulf 90 ± 5 87 ± 5 91 ± 7 91 ± 4 107 ± 3 113 ± 3 
APAP-d3-sulf 91 ± 16 90 ± 4 84 ± 4 91 ± 5 n/a n/a 
APAP-glut n/a 61 ± 4 57 ± 2 56 ± 9 132 ± 16 117 ± 15 
APAP-cys 381 ± 200 168 ± 29 109 ± 7 101 ± 4 114 ± 4 114 ± 3 
APAP-NAC 75 ± 3 73 ± 5 74 ± 3 n/a 104 ± 3 n/a 
 
a Reported values are mean % ± standard deviation. 
 



















Table 2.6 Ionization efficiency and matrix effect for determination of APAP and 
metabolites in human urine. 
 
Compound 
Ionization efficiency (%)a (n = 5) 
Accuracy and  
imprecision of matrix 
effect samples (%)a  











APAP 100 ± 5 99 ± 5 99 ± 2 101 ± 4 97 ± 1 
APAP-d4 100 ± 6 103 ± 8 103 ± 9 n/a n/a 
APAP-gluc 96 ± 3 94 ± 3 94 ± 3 107 ± 12 99 ± 8 
APAP-sulf 101 ± 4 99 ± 4 97 ± 3 112 ± 4 115 ± 2 
APAP-d3-sulf 100 ± 7 103 ± 7 102 ± 6 n/a n/a 
APAP-glut 99 ± 4 99 ± 3 99 ± 4 101 ± 5 112 ± 8 
APAP-cys 104 ± 5 99 ± 5 99 ± 4 108 ± 5 107 ± 1 
APAP-NAC 99 ± 4 98 ± 2 98 ± 4 87 ± 4 91 ± 1 
 
a Reported values are mean % ± standard deviation. 
 














Analyte stock solutions appeared stable (within ±20% of freshly prepared 
solution) following 6 months of storage at −20°C. After 12 months of storage at −20°C, 
APAP-glut stock solution had deteriorated to less than 40% of the values obtained from 
fresh stock solution; however, significant deterioration was not observed for any of the 
other analyte stock solutions. Based on these results, it was determined that APAP, 
APAP-gluc, APAP-sulf, APAP-cys, and APAP-NAC stock solutions could be used up to 
1 year after the preparation date, and APAP-glut stock solution could be used up to 6 
months after the preparation date. 
Results of plasma stability experiments are summarized in Table 2.7. Under all 
tested storage and handling conditions, APAP-glut quickly deteriorated in human plasma, 
presumably as a result of hydrolysis by gamma-glutamyl transpeptidase and dipeptidases. 
APAP-cys is a major hydrolysis product of APAP-glut, and the decline in APAP-glut was 
accompanied by a concomitant increase in APAP-cys concentrations. For many analytes, 
such instability would be cause for concern. However, in this case, investigators are often 
primarily interested in using the sum of APAP-glut, APAP-cys, and APAP-NAC 
concentrations as a surrogate for the amount of NAPQI that formed. Thus, APAP-glut 
instability is not a major concern here because the critical information is essentially 
retained through measurement of APAP-cys. Furthermore, these stability data were 
derived from fortified APAP-glut concentrations, which are likely far higher than 
physiologically relevant concentrations. In in vitro experiments with human fetal and 
adult liver homogenates, APAP-glut was rapidly transformed to APAP-cys [21]. 

















(n = 3) 
24 h at room 
temperature 




72 h in 5°C 
autosampler 
APAP 
0.15 99 ± 8 103 ± 10 102 ± 6 95 ± 5 
40 109 ± 9 102 ± 8 105 ± 9 98 ± 8 
APAP-gluc 
0.15 105 ± 6 99 ± 13 96 ± 3 101 ± 7 
40 120 ± 11 96 ± 10 97 ± 9 111 ± 4 
APAP-sulf 
0.15 97 ± 12 103 ± 9 82 ± 8 102 ± 9 
40 112 ± 8 101 ± 8 102 ± 7 98 ± 6 
APAP-glut 
0.080 0 ± n/a 35 ± 3 15 ± 1 94 ± 4 
4.0 0.16 ± 0.03 46 ± 4 23 ± 2 107 ± 7 
APAP-cys 
0.015 365 ± 29 127 ± 11 197 ± 31 90 ± 10 
4.0 307 ± 24 123 ± 13 160 ± 17 97 ± 6 
APAP-NAC 
0.015 94 ± 10 74 ± 16 90 ± 11 102 ± 14 
0.80 106 ± 8 87 ± 10 100 ± 7 98 ± 7 
 
a Reported values are mean % of initial observed concentration ± standard deviation. 
Stability of the analytes in plasma was assessed with fortified samples obtained by 
reconstitution of evaporated analyte working solutions in analyte- and IS-free plasma.  
 
b Reported values are mean % of observed concentration from freshly prepared samples ± 
standard deviation. 
 






suggests that hydrolysis of APAP-glut by gamma-glutamyl transpeptidase is the rate-
limiting step in the conversion to APAP-cys [21]. The results reported herein also 
indicate that substantial gamma-glutamyl transpeptidase and dipeptidase activities are 
present in human plasma. Thus, circulating concentrations of APAP-glut in humans are 
likely to be quite low. Nevertheless, if a particular research question required 
differentiation between relative amounts of APAP-glut and APAP-cys, it seems likely 
that addition of peptidase inhibitors during sample collection would prevent or at least 
minimize APAP-glut degradation, but such experiments were beyond the scope of this 
study. 
APAP, APAP-gluc, and APAP-sulf were adequately stable in human plasma 
under all tested storage and handling conditions (Table 2.7). For these analytes, mean 
concentrations were within ±20% of initial values following storage of fortified human 
plasma at room temperature for 24 h, at −80°C for 6 months, and after 3 freeze-thaw 
cycles. These results are in agreement with previous studies where APAP [26, 31-34] and 
APAP-gluc [26] have been found to be quite stable in human plasma under typical 
sample handling conditions. The results for stability of APAP-cys in human plasma were 
obscured due to the degradation of APAP-glut to APAP-cys. However, previous work 
has shown that APAP-cys was adequately stable in human plasma/serum for up to 24 h at 
room temperature and through 3 freeze-thaw cycles [26, 29, 30]. APAP-NAC appeared 
adequately stable in human plasma following 24 h of storage at room temperature and 
after 3 freeze-thaw cycles, but significant deterioration was evident at QC level 1 after 6 
months of storage at −80°C (mean stability: 74% of initial concentration). After only 1 




at 88 ± 8% and 93 ± 11%, respectively (mean % of initial observed concentration ± SD). 
All analytes were adequately stable in prepared plasma samples that were stored in the 
autosampler at 5°C for up to 72 h. Across all analytes and QC concentrations, mean 
concentrations of postpreparative stability samples were within ±11% of freshly prepared 
QC samples (Table 2.7). Taken together, the stability experiment results suggest that 
plasma samples can be handled at room temperature during routine sample preparation 
and subjected to several freeze-thaw cycles without concern for analyte degradation. 
Furthermore, plasma samples should ideally be assayed within the first few months after 
sample collection. 
Results of urine stability experiments are summarized in Table 2.8. APAP-glut 
was not detected in the initial urine stability samples (see further discussion below), but 
all other analytes were adequately stable in human urine under the tested storage and 
handling conditions. For these analytes, mean concentrations were within ±19% of initial 
concentrations following storage of human urine at room temperature for 24 h, at −80°C 
for 1 month, and after 3 freeze-thaw cycles. Additionally, all analytes were adequately 
stable in prepared urine samples that were stored in the autosampler at 5°C for up to 72 h. 
Mean concentrations of postpreparative stability samples were within ±10% of freshly 
prepared QC samples. 
 
Application to neonatal pharmacokinetic samples 
The methods presented in this paper have been successfully applied for 
determination of APAP and metabolites in the plasma and urine of neonatal clinical study 







Table 2.8 Stability of APAP and metabolites in human urine. 
 
Analyte 




24 h  
at room 
temperature 







72 h in 5°C 
autosampler 
APAP 
1.5 103 ± 3 96 ± 7 98 ± 4 7.5 98 ± 1 
15 108 ± 4 81 ± 3 99 ± 1 500 97 ± 8 
APAP-
gluc 
54 100 ± 7 92 ± 3 94 ± 5 7.5 101 ± 9 
489 99 ± 6 82 ± 5 91 ± 7 500 98 ± 11 
APAP-
sulf 
43 98 ± 2 99 ± 4 98 ± 3 7.5 102 ± 3 
416 108 ± 5 86 ± 6 102 ± 1 500 102 ± 8 
APAP-
glut 
<0.10 n/a n/a n/a 0.75 106 ± 3 
<0.10 n/a n/a n/a 50 103 ± 9 
APAP-
cys 
2.1 98 ± 5 106 ± 14 96 ± 4 0.75 104 ± 7 
21 104 ± 6 90 ± 5 96 ± 4 50 105 ± 12 
APAP-
NAC 
1.4 103 ± 8 99 ± 9 91 ± 5 0.75 110 ± 9 
14 111 ± 6 89 ± 5 96 ± 4 50 106 ± 12 
 
a Reported values are mean % of initial observed concentration ± standard deviation. 
Stability of the analytes in urine was assessed with samples prepared by dilution of a 
specimen collected from a volunteer approximately 3 h after ingestion of 1 g of APAP. 
 
b Reported values are mean % of observed concentration from freshly prepared samples ± 
standard deviation. 
 







from this special patient population was greatly facilitated by minimizing the required 
sample volume (10 µL). Each pharmacokinetic sample consisted of only 200 µL of 
blood, so most plasma sample volumes were less than 100 µL. Representative MRM 
chromatograms from the plasma assay show all analytes to be <LLOQ in a predose 
sample (Figure 2.4a) and APAP, APAP-gluc, APAP-sulf, APAP-cys, and APAP-NAC 
concentrations that are well above LLOQ in a sample collected from the same clinical 
study participant approximately 7 h after the first 15 mg/kg dose (Figure 2.4b). Similar 
representative MRM chromatograms are provided for pre and postdose urine samples in 
Figure 2.5. 
The percentage of postdose plasma and urine samples that were <LLOQ did not 
exceed 1% for most analytes (Table 2.9). The exception was APAP-glut, which was 
<LLOQ in nearly all plasma samples and in all of the urine samples. However, this was 
not unexpected because APAP-glut is thought to be particularly short-lived in humans, 
perhaps due to relatively high expression of gamma-glutamyl transpeptidase compared to 
other species [21, 35]. Additionally, results of stability experiments with fortified plasma 
showed that APAP-glut was rapidly converted to APAP-cys under routine storage and 
handling conditions (Table 2.7). In spite of these expectations, APAP-glut was included 
as an analyte in these assays because it is a critical intermediate in APAP metabolism, 
and the ability to quantitate APAP-glut makes the assays readily adaptable to other 
matrices where concentrations are anticipated to be quantifiable, such as rodent plasma, 
bile, and tissue [20, 22, 36]. 
The majority of the samples did not require dilution in order to fall within the 












Figure 2.4 Representative MRM chromatograms for determination of APAP and 
metabolites in human plasma: a predose plasma sample from a clinical study participant, 
b a plasma sample collected from the same clinical study participant approximately 7 h 
after the first 15 mg/kg dose. Specific precursor→product ion transitions for each analyte 
and IS are provided in Table 2.2. Solid lines depict MRM traces for quantifier transitions 
and dashed lines depict MRM traces for qualifier transitions. All analytes in a were 
determined to be <LLOQ. Interpolated analyte concentrations in b are provided in the 












Figure 2.5 Representative MRM chromatograms for determination of APAP and 
metabolites in human urine: a predose urine sample from a clinical study participant, b a 
4-h urine sample collected from the same clinical study participant approximately 1 h 
after the fourth 15 mg/kg dose. Specific precursor→product ion transitions for each 
analyte and IS are provided in Table 2.2. Solid lines depict MRM traces for quantifier 
transitions and dashed lines depict MRM traces for qualifier transitions. All analytes in a 
were determined to be <LLOQ. Interpolated analyte concentrations in b are provided in 















Table 2.9 Assay suitability for analysis of neonatal pharmacokinetic samples. 
 
Analyte 
Samples < LLOQ (%) Undiluted samples > ULOQ (%) 
Plasmaa Urineb Plasmaa Urineb 
APAP 0 1 0 0 
APAP-gluc 0 1 0 0 
APAP-sulf 0 1 9 3 
APAP-glut 97 100 0 0 
APAP-cys 0 1 8 5 
APAP-NAC 1 1 34 11 
 
a n = 267 postdose samples. 
 

















percentage of samples requiring dilution (34%), which was largely a consequence of the 
fact that the upper range of the APAP-NAC plasma curve was limited in order to 
maintain a linear fit. Those samples with analyte concentrations above the ULOQ 
required only minor dilution (no more than 10 fold), and they could easily be anticipated 




A novel HPLC–ESI–MS/MS procedure for simultaneous quantification of APAP 
and five APAP metabolites in small volumes (10 µL) of human plasma and urine was 
developed and successfully validated. The utility, sensitivity, and suitability of the assays 
were demonstrated by analysis of samples from a pharmacokinetic study of intravenous 
APAP in neonates. The reported methods were found to be sensitive, specific, accurate, 
precise, and efficient. These new methods will serve as powerful tools for researchers 
studying APAP pharmacokinetics and APAP-induced hepatotoxicity. 
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DEVELOPMENT OF A PARENT–METABOLITE 
POPULATION PHARMACOKINETIC MODEL  
FOR INTRAVENOUS PARACETAMOL  






This study aimed to model the population pharmacokinetics of intravenous 
paracetamol and its major metabolites in neonates and to identify influential patient 
characteristics, especially those affecting the formation clearance (CLformation) of oxidative 
pathway metabolites. Neonates with a clinical indication for intravenous analgesia 
received five 15 mg/kg doses of paracetamol at 12-h intervals (<28 weeks’ gestation) or 
seven 15 mg/kg doses at 8-h intervals (≥28 weeks’ gestation). Plasma and urine were 
sampled throughout the 72-h study period. Concentration–time data for paracetamol, 
paracetamol-glucuronide, paracetamol-sulfate, and the combined oxidative pathway 
metabolites (paracetamol-cysteine and paracetamol-N-acetylcysteine) were 
simultaneously modeled in NONMEM 7.2. The model incorporated 259 plasma and 350 
urine samples from 35 neonates with mean gestational age of 33.6 weeks (standard 
deviation 6.6). CLformation for all metabolites increased with weight; CLformation for 
glucuronidation and oxidation also increased with postnatal age. At the mean weight (2.3 
kg) and postnatal age (7.5 days), CLformation estimates (bootstrap 95% confidence interval; 
between-subject variability) were 0.049 L/h (0.038–0.062; 62%) for glucuronidation, 
0.21 L/h (0.17–0.24; 33%) for sulfation, and 0.058 L/h (0.044–0.078; 72%) for oxidation. 
Expression of individual oxidation CLformation as a fraction of total individual paracetamol 
clearance showed that, on average, fractional oxidation CLformation increased <15% when 
plotted against weight or postnatal age. The parent–metabolite model successfully 
characterized the pharmacokinetics of intravenous paracetamol and its metabolites in 
neonates. Maturational changes in the fraction of paracetamol undergoing oxidation were 





Paracetamol (N-acetyl-p-aminophenol, acetaminophen) is commonly used to 
manage mild to moderate pain in neonates [1, 2]. Intravenous formulations of the drug 
have only become available recently but have rapidly been adopted into clinical practice 
for applications in which enteral delivery is unsuitable, such as postoperative analgesia 
[3]. Several neonatal studies have characterized the pharmacokinetics of intravenous 
paracetamol [4-7]. 
Paracetamol primarily undergoes hepatic elimination, so markers of hepatic 
maturation and function are critical for explaining between-subject variability in 
paracetamol pharmacokinetics [4-6, 8, 9]. Metabolism also plays a key role in 
paracetamol-induced hepatotoxicity, which is a principal safety concern associated with 
use of the drug [10, 11]. The nontoxic products of glucuronidation and sulfation are 
efficiently excreted in urine, but paracetamol also undergoes oxidation by cytochrome 
P450 (CYP) enzymes, predominantly CYP2E1, to form the reactive intermediate N-
acetyl-p-benzoquinone imine (NAPQI). This electrophile can be detoxified by 
conjugation with glutathione, and rapid, subsequent metabolism of paracetamol-
glutathione produces paracetamol-cysteine and paracetamol-N-acetylcysteine. However, 
sufficiently high doses of paracetamol will saturate the glutathione detoxification 
pathway. Excess NAPQI binds covalently to hepatic proteins, and toxicity is thought to 
result from a combination of the inactivation of critical hepatic proteins and oxidative 
stress [12, 13]. 
Susceptibility to paracetamol-induced hepatotoxicity is likely influenced by 




shown that body weight is the principal predictor of intravenous paracetamol 
pharmacokinetics in extremely preterm to full-term neonates [4, 7]. These findings 
support implementation of a parsimonious neonatal dosing regimen based solely on 
equivalent per-kilogram dosing, without a requirement for different doses or dosing 
intervals dependent upon gestational or postmenstrual age [4]; however, these studies 
only utilized pharmacokinetic data for parent drug, which may not reflect maturational 
differences in the pharmacokinetics of hepatotoxicity-associated metabolites. 
Unfortunately, neonatal pharmacokinetic data for paracetamol metabolites remain scarce 
across all routes of administration, and previous studies that have incorporated metabolite 
data focused only on glucuronide and sulfate conjugates [6, 14-18]. 
The aim of this study was to develop a parent–metabolite population 
pharmacokinetic model for intravenous paracetamol in neonates to (i) estimate 
pharmacokinetic parameters for all major metabolic pathways of paracetamol, (ii) 
quantify between-subject variability in metabolite pharmacokinetics, and (iii) identify 
patient characteristics (covariates) that influence metabolite pharmacokinetic parameters, 
with a particular focus on formation clearance of the oxidative pathway metabolites 
(paracetamol-cysteine and paracetamol-N-acetylcysteine). 
 
Methods 
Study design and population 
This was a prospective, single-center, open-label study of the pharmacokinetics of 
intravenous paracetamol in neonates. The study was approved by the Institutional Review 




accordance with good clinical practice. Written informed consent was obtained from a 
parent or legal guardian prior to study inclusion. The study was registered at 
ClinicalTrials.gov (NCT01328808). 
Patients <28 days’ postnatal age with an indwelling arterial line and a clinical 
indication for intravenous analgesia who were admitted to intensive care units at 
Children’s National Health System were considered for inclusion. Exclusion criteria were 
severe asphyxia, grade III or IV intraventricular hemorrhage, major congenital 
malformations, neurological disorders, receipt of neuromuscular blockers, and hepatic or 
renal failure, including systemic hypoperfusion. Intravenous paracetamol (Ofirmev, 10 
mg/mL, Mallinckrodt Pharmaceuticals, Dublin, Ireland) was administered by 30-min 
infusions at 15 mg/kg/dose. Neonates <28 weeks’ gestation received 5 doses at 12-h 
intervals; neonates ≥28 weeks’ gestation received 7 doses at 8-h intervals. 
 
Sampling procedure and analytical methods 
Blood samples (0.2 mL) were obtained from arterial lines at approximately 0, 1, 
2, 4, 6, 8, 12, and 24 h after the first and final paracetamol doses. Patients were randomly 
assigned to one of two blood sampling schedules, each consisting of 9–10 collection 
times. Blood was collected in sodium heparin Vacutainer tubes (BD, Franklin Lakes, NJ) 
and centrifuged for 10–15 min at 1500 x g at 4°C. Plasma was transferred to cryovials 
and stored at −70°C. Urine samples were collected via indwelling catheter (postoperative 
patients) or from gel-free study diapers (procedural patients; Cuddle Buns Preemie 
diapers, Small Beginnings Inc., Hesperia, CA) at 3-4-h intervals over the 24 h following 




aliquots were reserved and stored at −70°C. Study samples were shipped on dry ice to the 
Center for Human Toxicology at the University of Utah and stored at −80°C prior to 
analysis. 
Plasma and urinary concentrations of paracetamol, paracetamol-glucuronide, 
paracetamol-sulfate, paracetamol-cysteine, and paracetamol-N-acetylcysteine were 
determined by high-performance liquid chromatography–electrospray ionization–tandem 
mass spectrometry according to the methods reported in Chapter 2. Mean intra- and inter-
assay accuracy ranged from 85–111%, and intra- and inter-assay imprecision did not 
exceed 15% coefficient of variation (CV). In plasma, the lower limit of quantification 
(LLOQ) was 0.05 mg/L for paracetamol, paracetamol-glucuronide, and paracetamol-
sulfate, and 0.01 mg/L for paracetamol-cysteine and paracetamol-N-acetylcysteine. In 
urine, the LLOQ was 0.2 mg/L for paracetamol, 1 mg/L for paracetamol-glucuronide and 
paracetamol-sulfate, and 0.1 mg/L for paracetamol-cysteine and paracetamol-N-
acetylcysteine. 
 
Base model development 
All concentrations were expressed in paracetamol equivalents (mg/L) via 
conversion based on molecular weights. Following conversion to paracetamol 
equivalents, paracetamol-cysteine and paracetamol-N-acetylcysteine concentrations for 
each sample were summed to approximate the total concentration of metabolites derived 
from CYP-mediated oxidation. The parent–metabolite pharmacokinetic model was 
developed using NONMEM 7.2 (nonlinear mixed effects modeling, ICON Development 




psn.sourceforge.net) and Pirana 2.9.0 (pirana-software.com). Urinary concentrations and 
urine sample volumes were included as NONMEM data items so that the software 
program could scale appropriately to urinary amounts [19]. Population parameters were 
estimated using the first-order conditional estimation with interaction method and the 
ADVAN6 subroutine. The number of significant digits required for convergence (NSIG), 
predicted values (TOL), and the objective function (SIGL) was set, respectively, to 2, 6, 
and 6 [20]. Processing and visualization of NONMEM output were performed in R 3.2.1 
(CRAN.R-project.org). Throughout model development, standard diagnostic plots were 
generated to evaluate model fit, including observations versus population predictions, 
observations versus individual predictions, conditional weighted residuals versus time, 
and conditional weighted residuals versus population predictions. During covariate 
analysis, nested models were compared using the objective function value (OFV). At all 
other stages of development, model discrimination was based on the Akaike Information 
Criterion (AIC) [21]. 
A schematic representation of the base structure for the parent–metabolite 
pharmacokinetic model is shown in Figure 4.1. The structural model incorporated the rate 
and duration of the intravenous paracetamol infusion. Paracetamol, paracetamol-
glucuronide, paracetamol-sulfate, and the combined oxidative pathway metabolites 
(paracetamol-cysteine and paracetamol-N-acetylcysteine) were each modeled with a 
single plasma compartment and subsequent urinary compartment. Similar structural 
models have been employed to describe the pharmacokinetics of intravenous paracetamol 
and its metabolites in adult surgical patients [22] and in women during the peripartum 















Figure 4.1 Schematic representation of the structural pharmacokinetic model for 
paracetamol and its metabolites in plasma (circles) and urine (squares). Abbreviations: 
CP, CG, CS, and CO represent, respectively, plasma concentrations of paracetamol, 
paracetamol-glucuronide, paracetamol-sulfate, and the combined oxidative pathway 
metabolites (paracetamol-cysteine and paracetamol-N-acetylcysteine); AP, AG, AS, and 
AO represent, respectively, urinary amounts of unchanged paracetamol, paracetamol-
glucuronide, paracetamol-sulfate, and the oxidative pathway metabolites; VP, VG, VS, and 
VO represent, respectively, volumes of distribution for paracetamol, paracetamol-
glucuronide, paracetamol-sulfate, and the oxidative pathway metabolites; CLfG, CLfS, and 
CLfO represent, respectively, formation (hepatic) clearances for paracetamol-glucuronide, 
paracetamol-sulfate, and the oxidative pathway metabolites; CLRP, CLRG, CLRS, and CLRO 
represent, respectively, renal clearances for unchanged paracetamol, paracetamol-
glucuronide, paracetamol-sulfate, and the oxidative pathway metabolites. All formation 











based on previous work with parent drug data from the same dataset [7]. The model 
structure required the assumption that the pathways illustrated in Figure 4.1 account for 
all elimination of paracetamol and its metabolites. All formation (hepatic) and renal 
clearances were modeled as first-order processes. Reith et al. modeled the Michaelis-
Menten kinetics of paracetamol glucuronidation, sulfation, and oxidation in healthy 
adults undergoing third molar dental extraction and found evidence of slight saturation 
occurring for sulfation and oxidation at a dose of 90 mg/kg [24]; thus, an assumption of 
first-order kinetics does not seem unreasonable given the doses administered in the 
present study. In total, the model was defined by 8 differential equations and 11 
pharmacokinetic parameters. 
Random effects were classified as between-subject variability (BSV) or residual 
unexplained variability (RUV). Individual pharmacokinetic parameters were assumed to 
be log-normally distributed, and BSV was modeled exponentially (Equation 4.1): 
 
 𝑃𝑃𝑖𝑖 = 𝜃𝜃𝑝𝑝𝑝𝑝𝑝𝑝 × 𝑒𝑒𝜂𝜂𝑖𝑖 (4.1) 
 
where Pi is the individual pharmacokinetic parameter, θpop is the population mean for P, 
ηi is the between-subject random effect on P for individual i, and ηi is normally 
distributed with a mean of 0 and a variance of ω2. Additive, proportional, and combined 








Potential covariates included current body weight, postnatal age, postmenstrual 
age, indication (postoperative or procedural), sex, race (Caucasian or African American), 
ethnicity, occasion (first or second), urine flow rate, and estimated glomerular filtration 
rate (GFR). The first and second occasions were defined, respectively, as ≤ and >42 h 
after the first paracetamol dose. Average flow rate for each urine sample was calculated 
by dividing the sample volume (mL) by the time elapsed during sample collection (h). 
Estimated GFR was calculated from body length and serum creatinine (modified kinetic 
Jaffe method) using the updated Schwartz formula [26]. Laboratory samples were 
obtained within 24 h prior to the first paracetamol dose or during the pharmacokinetic 
sample collection period. Serum creatinine concentrations obtained at ≤3 days’ postnatal 
age were considered to reflect maternal renal function and were excluded from analysis. 
During covariate analysis, subjects with missing information for a covariate undergoing 
evaluation were excluded from both the base and covariate models being tested. 
Due to the large number of potential covariate–pharmacokinetic parameter 
combinations, only the most physiologically relevant covariate–parameter pairs were 
considered. Categorical covariates were considered for inclusion using proportional shift 
models (Equation 4.2): 
 
 𝑃𝑃𝑖𝑖 = �𝜃𝜃𝑝𝑝𝑝𝑝𝑝𝑝 + 𝜃𝜃𝑝𝑝𝑝𝑝𝑝𝑝 × 𝜃𝜃𝑐𝑐𝑝𝑝𝑐𝑐 × 𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖� × 𝑒𝑒𝜂𝜂𝑖𝑖 (4.2) 
 
where Pi is the individual pharmacokinetic parameter, θpop is the population mean for P 




when COVi is 1, and ηi is the between-subject random effect on P for individual i. 
Current body weight, postnatal age, postmenstrual age, indication, and sex were 
tested on all pharmacokinetic parameters. For these covariates, continuous variables were 
normalized to population mean values and tested for inclusion in a power function 
(Equation 4.3): 
 
 𝑃𝑃𝑖𝑖 = 𝜃𝜃𝑝𝑝𝑝𝑝𝑝𝑝 × � 𝐶𝐶𝑂𝑂𝑂𝑂𝑖𝑖𝐶𝐶𝑂𝑂𝑂𝑂𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚�𝜃𝜃𝑐𝑐𝑐𝑐𝑐𝑐 × 𝑒𝑒𝜂𝜂𝑖𝑖 (4.3) 
 
where Pi is the individual pharmacokinetic parameter for an individual with covariate 
value COVi, θpop is the population mean for P when COVi equals the mean covariate 
value COVmean, θcov is the covariate effect, and ηi is the between-subject random effect on 
P for individual i. Given the potential for genetically mediated differences in paracetamol 
metabolism [27, 28], race and ethnicity were tested on all metabolite formation 
clearances (Equation 4.2). Additionally, occasion was tested on all metabolite formation 
clearances (Equation 4.2) because previous work has suggested that upregulation of 
paracetamol glucuronidation occurs with repeated administration in adults [29, 30] and in 
neonates [17, 31]. Finally, urine flow rate and estimated GFR were tested on all renal 
clearances. Based on a previous pharmacokinetic model of paracetamol, paracetamol-
glucuronide, and paracetamol-sulfate in infants, an exponential function was used for 
incorporation of urine flow rate [32] (Equation 4.4): 
 





where Pij is the pharmacokinetic parameter for individual i at time j with urine flow rate 
UFLOWij, θpop is the population mean for P when UFLOWij equals the median urine flow 
rate UFLOWmed (6.5 mL/h), θcov is the covariate effect, and ηi is the between-subject 
random effect on P for individual i. Estimated GFR was tested in a mean-centered power 
function (Equation 4.3). 
Potential covariates were tested using a modified stepwise forward selection 
procedure followed by stepwise backward elimination. Changes in OFV were considered 
significant at p < 0.05 (χ2 distribution, 1 degree of freedom, ΔOFV > 3.84) during 
forward selection and p < 0.01 (ΔOFV > 6.63) during backward elimination [33]. 
Additionally, covariates were required to provide at least 5% reduction in BSV or RUV 
in order to be added to or retained in the model. The modified forward selection was 
conducted in a series of rounds. In round 1, weight was tested on all pharmacokinetic 
parameters and subsequently included on all parameters for which selection criteria were 
met. In round 2, the remaining covariate–parameter pairs of interest were tested. Round 3 
consisted of standard stepwise forward selection using only those covariate–parameter 
pairs that met selection criteria in round 2. Rounds 2 and 3 were repeated until none of 
the remaining covariate–parameter pairs met the selection criteria, at which point 
standard stepwise backward elimination was performed. 
 
Model refinement 
Following covariate analysis, the model was refined by testing the validity of the 
default assumption that random effects exhibit no covariance. The extent of covariance in 




in RUV terms was evaluated by estimating off-diagonal elements of the Σ matrix, which 
required utilization of the NONMEM L2 data item for designation of multivariate 
observations [19]. Finally, all covariates included in the model were tested by backward 
elimination to ensure that covariate criteria were still met after model refinement. 
 
Model evaluation 
A nonparametric bootstrap was performed to assess the stability of the final model 
and to quantify uncertainty in parameter estimates [34]. Bootstrap datasets (n = 200) were 
generated in PsN by random sampling with replacement from the original dataset. 
Additionally, normalized prediction distribution errors (NPDE) based on 1000 
simulations were calculated in NONMEM, and plots were generated for NPDE 




Patients and pharmacokinetic observations 
Demographic characteristics of the 35 study subjects are summarized in Table 
4.1. Most patients (66%) received the first paracetamol dose within 1 week after birth. 
Concentrations of paracetamol, paracetamol-glucuronide, paracetamol-sulfate, and 
oxidative pathway metabolites were available from 266 plasma samples and 352 urine 
samples. Six plasma samples (2%) had implausible drug concentrations (e.g., peak 
concentrations observed at trough collection times) and were excluded from analysis. 




Table 4.1 Demographic characteristics of neonates who received intravenous 
paracetamol. 
 
Characteristic n (%) Mean ± SD (range) 
Gestational age (weeks) 35 (100) 33.6 ± 6.57 (23–41) 
Postnatal agea (days) 35 (100) 7.49 ± 5.73 (1–26) 
Postmenstrual agea (weeks) 35 (100) 34.6 ± 6.28 (23.1–41.6) 
Current body weighta (kg) 35 (100) 2.30 ± 1.22 (0.46–4.20) 
Current body lengtha (cm) 34 (97) 43.4 ± 9.15 (25.0–56.0) 
Current body weighta (kg) by gestational age 
Extreme preterm, <28 weeks’ GA 10 (29) 0.81 ± 0.27 (0.55–1.30) 
Preterm, <37 weeks’ GA (includes <28 weeks’ GA) 17 (49) 1.22 ± 0.76 (0.46–2.80) 
Full-term, 37–42 weeks’ GA 18 (51) 3.32 ± 0.39 (2.70–4.20) 
Serum creatinineb (mg/dL) 30 (86) 0.707 ± 0.242 (0.3–1.1) 
Estimated GFRc (mL/min/1.73 m2) 29 (83) 30.1 ± 16.6 (12.6–70.9) 
Primary indication for intravenous paracetamol 
Postoperative analgesia (cardiac surgery) 19 (54) - 
Procedural analgesia 16 (46) - 
Sex 
Male 20 (57) - 
Female 15 (43) - 
Race 
Caucasian 16 (46) - 
African American 14 (40) - 
American Indian/Alaska Native 1 (3) - 
Asian 1 (3) - 
Declined to respond 3 (9) - 
Ethnicity 
Non-Hispanic 24 (69) - 
Hispanic 8 (23) - 
Declined to respond 3 (9) - 
 
a On the day of the first paracetamol dose. 
b Serum creatinine concentrations obtained at ≤3 days’ postnatal age were considered to 
reflect maternal renal function and were excluded from analysis. 
c Estimated GFR was calculated using the updated Schwartz formula [26]. 




all analytes were <LLOQ. Three plasma samples (1%) had paracetamol-N-acetylcysteine 
concentrations <LLOQ, and 2 urine samples (<1%) had one analyte <LLOQ 
(paracetamol or paracetamol-glucuronide); values of LLOQ÷2 were used in these 
instances [36]. Thus, 259 plasma samples (median: 8; range: 3–11 samples/patient) and 
350 urine samples (median: 11; range: 2–16 samples/patient) were used to develop the 
population pharmacokinetic model. These samples provided a total of 1036 plasma 
concentrations and 1400 urinary concentrations. Figure 4.2 shows observed paracetamol 
and metabolite plasma concentrations over time following the first and final paracetamol 
doses. 
 
Population pharmacokinetic model development 
When additive, proportional, and combined additive and proportional error 
functions were tested for characterization of RUV, the combined function provided the 
lowest AIC and was selected for inclusion in the model. 
Based on covariate selection criteria, weight was incorporated into the final model 
on all pharmacokinetic parameters, postnatal age was included on formation clearances of 
paracetamol-glucuronide and oxidative pathway metabolites, urine flow rate was 
included on all renal clearances, and indication was included on renal clearance of 
unchanged paracetamol. Final estimates for covariate effects are provided in Table 4.2, 
along with estimates for pharmacokinetic parameters, BSV, and RUV. Current body 
weight had a strong influence on all pharmacokinetic parameters. When weight was 
included on each parameter during round 1 of the modified forward selection process, 















Figure 4.2 Observed plasma concentrations versus time for neonates who received 5 
doses at 12-h intervals (a and c, 15 mg/kg/dose) and for neonates who received 7 doses at 
8-h intervals (b and d, 15 mg/kg/dose). a and b show paracetamol concentrations (gray x 
marks); c and d show concentrations of paracetamol-glucuronide (blue plus signs), 
paracetamol-sulfate (green circles), and the combined oxidative pathway metabolites 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CV. Urine flow rate was also a highly significant covariate for all renal clearances. In the 
final model, removal of urine flow rate from each renal clearance produced increases in 
OFV ranging from 34.0–200.3. Effects of postnatal age and indication were more modest 
than those of weight and urine flow rate. When postnatal age and indication were 
excluded from the final model, increases in OFV ranged from 10.0–20.5 and increases in 
BSV ranged from 5–15% CV. 
Incorporation of covariance estimates for all BSV terms (i.e., a full Ω matrix) 
improved the model fit compared to the default condition of no covariance (i.e., a 
diagonal Ω matrix). Utilization of a full-covariance structure ensured that critical 
covariance terms would be included, and any ill effects from unnecessary covariance 
terms were expected to be minimal [37]. 
Given the physiological basis for the parent–metabolite structural model, it was 
anticipated that covariance of some parameters would be strong. Correlations in BSV for 
renal metabolite clearances were particularly high, with correlation coefficients ranging 
from 0.73–0.97. Attempting to estimate a correlation near 1 tends to cause numerical 
instabilities and can hinder model convergence. To avoid such problems, correlations in 
BSV for renal metabolite clearances were fixed to 1 using a previously reported approach 
[38]. Renal clearance of paracetamol-glucuronide was described according to the usual 
exponential form (Equation 4.1). To fix the correlation between random effects for renal 
clearance of paracetamol-glucuronide and paracetamol-sulfate to 1, renal clearance of 
paracetamol-sulfate was described as follows (Equation 4.5): 
 




where CLRS,i is the individual renal clearance of paracetamol-sulfate, θpop,CLRS is the 
population mean for renal clearance of paracetamol-sulfate, θscale,CLRS is a scale parameter 
between the variance of CLRG and the variance of CLRS (Equation 4.6), and ηi,CLRG is the 
between-subject random effect on renal clearance of paracetamol-glucuronide for 
individual i. Variance for renal clearance of paracetamol-sulfate could then be determined 
as follows (Equation 4.6): 
 
 𝐶𝐶𝑉𝑉𝑉𝑉(𝐶𝐶𝐶𝐶𝑅𝑅𝑅𝑅) = 𝜃𝜃𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠,𝐶𝐶𝑈𝑈𝑅𝑅𝑅𝑅2 × 𝐶𝐶𝑉𝑉𝑉𝑉�𝜂𝜂𝑖𝑖,𝐶𝐶𝑈𝑈𝑅𝑅𝑅𝑅� (4.6) 
 
The same approach was used to fix the correlation between random effects for renal 
clearance of paracetamol-glucuronide and the oxidative pathway metabolites to 1. Model 
fit suffered slightly when these correlations were fixed, as indicated by a 13.7 increase in 
AIC. However, this worsening of model fit was considered acceptable in exchange for 
enhanced model stability and a considerable reduction in the number of model parameters 
(19 fewer parameters). Final estimates for correlation in BSV are provided in Table 4.3. 
When covariance estimates on RUV terms from multivariate observations were 
incorporated into the model, the AIC decreased by 1520.4, indicating a substantial 
improvement in model fit compared to the default condition of no covariance. Once the 
covariance terms were included, most additive RUV variance estimates approached 0 and 
could be excluded from the model without compromising model fit. Additive RUV 
components were retained only for plasma paracetamol-sulfate, urinary paracetamol-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































terms were removed. The correlation between additive RUV for urinary paracetamol and 
paracetamol-sulfate was particularly high, with a correlation coefficient estimated at 1.0; 
therefore, this correlation was fixed to 1 using the approach shown in Equations 4.5 and 
4.6 to stabilize the model. Final estimates for correlation in proportional RUV are 
provided in Table 4.4. 
 
Model evaluation 
Standard diagnostic plots of observations versus population predictions and 
observations versus individual predictions are provided in Figure 4.3 to illustrate the final 
model fit. Bootstrap summary statistics for pharmacokinetic parameters, covariate effects, 
BSV, and RUV are provided in Table 4.2 alongside corresponding point estimates. 
Median bootstrap estimates were very similar to point estimates from the final model fit, 
and bootstrap 95% confidence intervals demonstrated reasonably good precision for most 
parameters. Point estimates and bootstrap-derived 95% confidence intervals are provided 
in Tables 4.3 and 4.4 for correlations in BSV and RUV, respectively. Many BSV 
correlations were estimated with poor precision (Table 4.3); however, this was not 
unexpected given the use of a full Ω matrix. In contrast, correlations in RUV were 
generally estimated with greater precision than those for BSV, and none of the 95% 
confidence intervals crossed 0 (Table 4.4). 
Out of 200 bootstrap runs, 153 (77%) minimized successfully, and all others 
failed due to rounding errors. Bootstrap summary statistics were derived only from 
successful runs; however, parameter estimates from successful and unsuccessful runs 
were largely in good agreement. For instance, when median bootstrap estimates from
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Figure 4.3 Diagnostic plots of observations versus predictions for the final model. 
Observed versus a population-predicted and b individual-predicted plasma 
concentrations, and observed versus c population-predicted and d individual-predicted 
urinary amounts for paracetamol (gray x marks), paracetamol-glucuronide (blue plus 
signs), paracetamol-sulfate (green circles), and the combined oxidative pathway 
metabolites (paracetamol-cysteine and paracetamol-N-acetylcysteine, orange triangles). 






successful and unsuccessful runs were compared, most of the parameters listed in Tables 
4.2 and 4.4 exhibited less than 5% difference (n = 55 out of 63 parameters, 87%), and all 
parameters in Tables 4.2 and 4.4 differed by less than 15%. Discrepancies between 
successful and unsuccessful runs were more evident for between-subject covariance 
terms (Table 4.3): in a comparison of median bootstrap estimates, most of these 
parameters differed by greater than 15% (n = 25 out of 36 parameters, 69%). It is 
plausible that rounding errors would tend to occur on unnecessary, poorly estimated 
between-subject covariance terms, thus generating larger discrepancies between 
successful and unsuccessful runs for those parameters. 
Simulation-based visualizations of model appropriateness were generated with 
NPDE, which are expected to have a mean of 0 and a variance of 1. NPDE distributions 
for plasma compartments showed reasonably good agreement with the expected standard 
normal distribution (Figure 4.4a), but urinary NPDE distributions exhibited greater 
deviation from expected values (Figure 4.4b). Importantly, there were no strong trends in 
NPDE when plotted against time since first dose (Figure 4.4c–d), population predictions 
(Figure 4.4e–f), or influential covariates (Figure 4.4g–j). 
Finally, in order to explore maturational trends in the fraction of paracetamol 
eliminated by the four routes shown in Figure 4.1, individual clearance estimates for each 
pathway were expressed as fractions of total individual paracetamol clearance and plotted 
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Figure 4.4 Plots of normalized prediction distribution errors (NPDE) for evaluation of 
the final model. NPDE for plasma concentrations (a, c, e, g, i) and urinary amounts (b, d, 
f, h, j) of paracetamol (gray x marks), paracetamol-glucuronide (blue plus signs), 
paracetamol-sulfate (green circles), and the combined oxidative pathway metabolites 
(paracetamol-cysteine and paracetamol-N-acetylcysteine, orange triangles). a and b show 
density histograms of NPDE for paracetamol (gray), paracetamol-glucuronide (blue), 
paracetamol-sulfate (green), and the oxidative pathway metabolites (orange) with 
overlaid black curves depicting standard normal distributions for comparison. NPDE are 
shown versus time (c [plasma] and d [urine]), population-predicted plasma concentration 
(e), population-predicted urinary amount (f), current body weight (g [plasma] and h 














 e f 
 
 
 g h 
 
 


















 i j 
 
 
















Figure 4.5 Fraction of total paracetamol clearance accounted for by glucuronidation, 
sulfation, oxidation, and renal clearance of unchanged parent drug. Fractional clearances 
for each subject (open black circles) are shown versus a current body weight and b 
postnatal age. The dashed red lines depict quasibinomial fits of the data, and the shaded 
gray regions depict 95% confidence intervals surrounding the regression curves. 
Fractional clearances were calculated from individual formation (hepatic) clearance 
estimates for paracetamol-glucuronide, paracetamol-sulfate, and the combined oxidative 
pathway metabolites (paracetamol-cysteine and paracetamol-N-acetylcysteine) and from 









This is the first neonatal study to describe the pharmacokinetics of paracetamol 
and its metabolites derived from glucuronidation, sulfation, and oxidation. In neonates, 
sulfation of paracetamol predominates, and the present observations on the relative 
elimination of paracetamol by glucuronidation, sulfation, or renal elimination of 
unchanged parent drug agree well with those from prior neonatal pharmacokinetic studies 
[6, 14-18]. One notable strength of the reported model was incorporation of both plasma 
and urinary concentrations of paracetamol and metabolites. Such observations made the 
model structurally identifiable with respect to metabolite volumes of distribution and 
renal clearances, thus allowing each of these parameters to be estimated. Volumes of 
distribution for paracetamol-glucuronide and paracetamol-sulfate were approximately 
40% of parent drug volume of distribution. This trend is logical given the increased 
hydrophilicity of these metabolites relative to parent drug, and it is consistent with 
previous estimates for paracetamol-glucuronide and paracetamol-sulfate volumes of 
distribution obtained from anephric patients [39]. All three renal metabolite clearances 
were fairly similar (0.10–0.17 L/h), in agreement with a prior study that found little 
variation between the same parameters in adult surgical patients [22]. 
A primary objective of this study was to explore maturational changes in 
pharmacokinetics of the oxidative pathway metabolites, which serve as markers for the 
toxic metabolite NAPQI. Weight and postnatal age were identified as covariates that 
significantly influenced formation clearance of the oxidative pathway metabolites. When 
weight was incorporated into the model, the OFV decreased by 50.3, and a reduction in 




additional OFV decrease of 20.5 and BSV reduction of 9% CV. Both weight and 
postnatal age were also significant covariates on formation clearance of paracetamol-
glucuronide. Collectively, these observations are consistent with previous evidence that 
hepatic CYP2E1 expression and UDP-glucuronosyltransferase expression and activity 
begin during gestation and increase rapidly during the first weeks of life [40, 41]. 
In extremely preterm to full-term neonates, total clearance of intravenous 
paracetamol is primarily influenced by body weight [4, 7, 42, 43], and the present 
findings expand upon prior knowledge by showing that clearances for all four 
paracetamol elimination routes were significantly affected by weight. Although the 
fractional clearance by glucuronidation appears relatively constant when plotted against 
postnatal age (Figure 4.5b), the fact that postnatal age was identified as a significant 
covariate on formation clearance of paracetamol-glucuronide is consistent with the 
anticipated marked increase in UDP-glucuronosyltransferase activity during early life 
[41]. On average, the fraction of drug undergoing oxidation increased slightly (<15%) 
with increasing weight or postnatal age, but these trends were small relative to BSV 
(Figure 4.5). Intravenous paracetamol has often been administered more conservatively to 
less mature neonates (e.g., at wider dosing intervals or in lower per-kilogram doses), but 
recent analyses of parent drug pharmacokinetics support utilization of a parsimonious 
regimen based only on equivalent per-kilogram dosing [4, 7]. The present findings 
indicate that such a dosing regimen also appears suitable with respect to the 
pharmacokinetics of hepatotoxicity-associated metabolites. 
Results from covariate analysis also corroborated a previous infant model in 




increased with urine flow rate [32]. In the current study, a similar influence of urine flow 
rate on renal clearance was also observed for the oxidative pathway metabolites. 
Additionally, renal clearance of unchanged paracetamol differed significantly between 
patients with postoperative and procedural indications. However, this finding should be 
interpreted cautiously. Key patient characteristics were distributed unevenly across the 
two groups: compared to postoperative patients, procedural patients tended to weigh less 
and have lower gestational ages and higher postnatal ages. Urine collection procedures 
also differed between postoperative and procedural patients (catheter and diaper, 
respectively). Furthermore, even if this covariate reflects a true physiological effect, it is 
unlikely to be clinically significant given the low fractional clearance of unchanged drug. 
The large BSV observed for most pharmacokinetic parameters highlights the 
importance of continued caution in administration of paracetamol to neonates. BSV was 
particularly high for glucuronidation and oxidation (62–72% CV), as might be expected 
based on the rapid development of these processes during early life [40, 41]. Future 
studies should incorporate additional patient information, such as genetic data, that could 
further reduce BSV. Urinary RUV also remained fairly high in the final model (Table 
4.2), which was not surprising given that urine sampling introduces more opportunities 
for error than plasma sampling (e.g., longer collection period and requirement for records 
of sample start time, end time, and volume). These urine-specific aspects of sample 
collection might also have contributed to the relatively high correlations in urinary RUV 
(Table 4.4). 
Interpretation of these findings is subject to several limitations. First, despite good 




still relatively small. Second, the model relies on the assumption that all elimination of 
paracetamol and its metabolites occurs via the pathways illustrated in Figure 4.1, but 
small fractions of paracetamol and its metabolites are known to undergo biliary excretion 
in humans [44, 45]. The model structure also fails to account for NAPQI that covalently 
binds proteins to form paracetamol protein adducts. This fraction of NAPQI is expected 
to be small relative to the amount conjugated to glutathione; nevertheless, future studies 
could explore this point more thoroughly by testing for covariate effects on the 
pharmacokinetics of circulating paracetamol protein adducts. Finally, although this study 
contributes critical information regarding the pharmacokinetics of paracetamol 
metabolites in neonates, pharmacodynamic data for paracetamol in this patient population 
are still lacking [46]. Further studies are needed for identification of appropriate 
pharmacodynamic targets for various indications (e.g., analgesia, antipyresis, or patent 
ductus arteriosus closure) [47, 48]. 
 
Conclusion 
The reported parent–metabolite model successfully characterized the 
pharmacokinetics of intravenous paracetamol and its metabolites in preterm and term 
neonates. Formation clearance of oxidative pathway metabolites increased with body 
weight and postnatal age; however, maturational increases in the fraction of drug 
undergoing oxidation were small relative to between-subject variability. 
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Summary of Findings 
This dissertation focused on the exploration of maturational changes in the 
pharmacokinetics of intravenous acetaminophen and its metabolites in neonates through 
completion of three primary aims. These aims centered on a prospective clinical trial in 
which neonates with a clinical indication for intravenous analgesia received 
acetaminophen (15 mg/kg/dose) for 5 doses at 12-h intervals (<28 weeks’ gestation) or 
for 7 doses at 8-h intervals (≥28 weeks’ gestation). Pharmacokinetic samples were 
collected throughout a 72-h study period. 
In the first aim (Chapter 2), novel HPLC–ESI–MS/MS methods were developed 
for application to the neonatal pharmacokinetic samples. The procedures were 
successfully validated for simultaneous quantification of acetaminophen, acetaminophen-
glucuronide, acetaminophen-sulfate, acetaminophen-glutathione, acetaminophen-
cysteine, and acetaminophen-N-acetyl-cysteine in small volumes (10 µL) of human 
plasma and urine. Acetaminophen-d4 and acetaminophen-d3-sulfate were utilized as 
internal standards. Analytes and internal standards were recovered from plasma by 
protein precipitation with acetonitrile, and urine samples were prepared by fortification 
with internal standards followed only by sample dilution. Calibration concentration 
ranges were carefully tailored to literature values for each analyte in each biological 
matrix. Prepared samples from plasma and urine were analyzed under the same HPLC–
ESI–MS/MS conditions, and chromatographic separation was achieved through use of an 
Agilent Poroshell 120 EC-C18 column with a 20-min run time per injected sample. 
The analytes could be accurately and precisely quantified over 2.0–3.5 orders of 




112%, and intra- and inter-assay imprecision did not exceed 15%. Validation experiments 
included tests for specificity, recovery and ionization efficiency, inter-individual 
variability in matrix effects, stock solution stability, and sample stability under a variety 
of storage and handling conditions (room temperature, freezer, freeze-thaw, and 
postpreparative). Both methods were found to be sensitive, specific, accurate, precise, 
and efficient. The reported procedures were successfully applied to the pharmacokinetic 
study samples. 
The second aim (Chapter 3) focused on the development of a population 
pharmacokinetic model for the parent drug data obtained from the neonatal 
pharmacokinetic study [1]. Nonlinear mixed effects models were constructed in 
NONMEM 7.2 using 260 acetaminophen concentration–time points from 35 patients. 
Potential covariates included body weight, gestational age, postnatal age, postmenstrual 
age, sex, race, total bilirubin, and estimated glomerular filtration rate. Importantly, there 
was good representation of extremely preterm, preterm, and term neonates among the 
study subjects. Data were well described by a one-compartment model with first-order 
elimination. In neonates ranging from extremely preterm to full-term gestational ages, 
body weight was the principal predictor of intravenous acetaminophen pharmacokinetics. 
Clearance and volume of distribution were estimated as 0.348 L/h (5.5% relative standard 
error; 30.8% between-subject variability) and 2.46 L (3.5% relative standard error; 14.3% 
between-subject variability), respectively, at the mean subject weight of 2.30 kg. 
In an external evaluation of the parent drug model with a dataset from a similar, 
independent clinical trial, the median prediction error was 10.1% (95% confidence 




confidence interval: 23.1–28.1%). These figures indicate that the parent drug model 
performed adequately despite notable study differences in the proportion of extremely 
preterm neonates, postnatal age, racial composition, and geographic location. Thus, these 
findings should be generalizable to other similar patient populations. 
The results from the second research aim largely reinforce and expand upon 
previous work that supported the use of a simplified neonatal dosing regimen in which 
maturational changes in acetaminophen pharmacokinetics could be accommodated using 
only equivalent per-kilogram dosing, without requiring different doses or dosing intervals 
dependent upon gestational or postmenstrual age [2]. Our findings suggest that extension 
of such a parsimonious dosing regimen to extremely preterm neonates is valid. 
In the third aim (Chapter 4), a parent–metabolite population pharmacokinetic 
model was developed using the data obtained from the neonatal pharmacokinetic study. 
Concentration–time data for acetaminophen, acetaminophen-glucuronide, 
acetaminophen-sulfate, and the combined oxidative pathway metabolites 
(acetaminophen-cysteine and acetaminophen-N-acetylcysteine) were simultaneously 
modeled in NONMEM 7.2. The model incorporated 259 plasma and 350 urine samples 
from 35 neonates. As part of the model development process, an extensive covariate 
analysis was performed to identify patient characteristics that influenced metabolite 
pharmacokinetic parameters, with a particular focus on formation clearance of the 
oxidative pathway metabolites. 
Formation clearances for all metabolites increased with weight, and formation 
clearances for glucuronidation and oxidation also increased with postnatal age. At the 




(bootstrap 95% confidence interval; between-subject variability) were 0.049 L/h (0.038–
0.062; 62%) for glucuronidation, 0.21 L/h (0.17–0.24; 33%) for sulfation, and 0.058 L/h 
(0.044–0.078; 72%) for oxidation. Fractional formation clearance of the oxidative 
pathway metabolites, which are associated with hepatotoxicity, increased slightly (<15%) 
with weight and postnatal age, but these maturational changes were small relative to 
between-subject variability. These findings extend the results from the previous aim by 
showing that the pharmacokinetics of acetaminophen metabolites also support utilization 
of parsimonious weight-based dosing; however, the large between-subject variability in 
metabolite pharmacokinetics underscores the importance of continued caution in 
administration of acetaminophen to neonates. 
The collective results from these studies substantially improve our understanding 
of the factors that influence acetaminophen disposition during the neonatal period, and 
this knowledge is critical for implementation of informed intravenous acetaminophen 
dosing strategies in this vulnerable patient population. Nevertheless, several areas of 
future investigation are warranted. 
 
Future Directions 
A major strength of the study reported in Chapter 3 was the incorporation of an 
external model evaluation. Ideally, such an evaluation would also be performed on the 
parent–metabolite model presented in Chapter 4; however, because this is the first 
neonatal study to describe the pharmacokinetics of acetaminophen and its metabolites 
derived from glucuronidation, sulfation, and oxidation, there are no data available for 




methods described in Chapter 2 to pharmacokinetic samples from previous clinical trials 
of intravenous acetaminophen in neonates in order to acquire metabolite data for external 
evaluation. Prior to such analysis, optimal design techniques could be applied to data 
from the present study to minimize the number of samples requiring quantitative analysis 
while maintaining the essential pharmacokinetic information [3]. Optimal design 
techniques could also be employed to identify optimal pharmacokinetic sampling 
schedules for future prospective studies in similar patient populations so that the number 
of blood samples drawn from each patient could be minimized. 
Based on the observed maturational trends in the fraction of acetaminophen 
undergoing oxidation (Figure 4.5), future work should also be devoted to exploring 
maturational changes in the pharmacokinetics of acetaminophen and its metabolites in 
infants. Historically, intravenous acetaminophen has often been administered more 
conservatively to less mature neonates, but the findings from Chapter 4 revealed that 
more mature neonates clear larger fractions of the drug via oxidation and glucuronidation 
and a smaller fraction via sulfation. Although the maturational increases in fractional 
clearance by oxidation were small relative to between-subject variability, it is possible 
that the observed trend continues into infancy. Moreover, only three neonates with 
postnatal ages >14 days were included in the present dataset, so the late neonatal period 
deserves further consideration in this regard, as well. 
In the parent–metabolite model, between-subject variability remained especially 
high for glucuronidation and oxidation (62–72% CV). This was not unexpected given the 
rapid development of these processes that occurs during early life [4-6]. Even so, future 




formation clearances to attempt to reduce between-subject variability. Genetic data 
represents a particularly promising option for further covariate testing, and a number of 
genetic polymorphisms have been shown to affect acetaminophen metabolism, primarily 
in in vitro enzyme activity studies with human liver preparations [7]. 
One potential limitation of the parent–metabolite model is its failure to account 
for NAPQI that covalently binds proteins to form acetaminophen protein adducts. This 
fraction of NAPQI is expected to be small relative to the amount conjugated by 
glutathione, but future studies could explore this point more thoroughly by measuring 
acetaminophen protein adducts in neonatal study samples and testing for covariate effects 
on the pharmacokinetics of circulating acetaminophen protein adducts. The material in 
the Appendix was supplied with such an application in mind. It should be emphasized, 
however, that the mechanism by which the protein adducts appear in the circulation in the 
absence of hepatic necrosis is unclear. Hepatic formation [8] and localization [9] of the 
adducts are highly correlated with toxicity. As hepatic necrosis progresses, 
acetaminophen protein adducts are released from hepatocytes into the circulation, and the 
adducts can be detected at high concentrations in the serum/plasma of humans and 
rodents following supratherapeutic acetaminophen ingestions [10-15]. Serum 
acetaminophen protein adducts have also been detected at lower concentrations in 
subjects taking therapeutic doses of the drug [16, 17], but circulating adduct 
concentrations are not necessarily correlated with hepatic concentrations under such 
circumstances. Therefore, it would likely be inappropriate to incorporate circulating 
acetaminophen protein adduct concentrations into a parent–metabolite model in the same 




previously proposed that detection of serum acetaminophen protein adducts above a 
threshold concentration of 1 nmol/mL is indicative of acetaminophen-induced 
hepatotoxicity [13], so it might be possible to incorporate the adducts into a model as a 
toxicodynamic marker based on this threshold. 
Perhaps the greatest need for future research related to the use of intravenous 
acetaminophen in neonates lies in the identification of appropriate pharmacodynamic 
targets. To date, only one pharmacodynamic study of intravenous acetaminophen has 
been performed in neonatal patients. Allegaert et al. evaluated their proposed 
parsimonious dosing regimen [2] (see Table 1.1) in 19 subjects who received intravenous 
acetaminophen as monotherapy for mild to moderate pain [18]. Pain was assessed using 
the Leuven Neonatal Pain Score (range: 0–14), which is a previously validated, 
multidimensional pain scale based on 7 measures (sleep, facial appearance, crying, heart 
rate, motor tone, movement, and consolability) [19]. A significant trend for lower pain 
scores within 30 min after administration was observed (repeated measures ANOVA, p = 
0.02) along with a nonsignificant increase in pain scores from 5–6 h. The maximum 
effect was a reduction in pain score of 4.15 units, and an effect compartment 
concentration of 10 mg/L was associated with a pain score reduction of 3.4 units. These 
results are encouraging because they agree fairly well with previous estimates obtained 
from children (9 ± 3 years of age) who received oral acetaminophen prior to 
tonsillectomy [20]; however, the study design suffered from a number of limitations. The 
number of subjects was small and observations were particularly sparse. Additionally, the 
study was not blinded because the primary outcome was collection of pharmacokinetic 




select initial target concentrations for neonatal pharmacodynamic studies based on target 
concentrations from pharmacodynamic studies performed in older children. 
The collection of robust pharmacodynamic data for intravenous acetaminophen in 
neonates will require substantial effort and resources. The efficacy of acetaminophen is 
known to be influenced not only by dose, but also by route of administration and 
indication, which includes variability in efficacy dependent upon the type of painful 
stimulus [21-23]. Efficacy in neonates may be further complicated by maturational 
processes. Additionally, neonatal pain assessment presents particular challenges, such as 
significant subjectivity and interobserver variability. As a consequence of existing 
limitations in neonatal pain assessment methods, efforts are currently underway to 
develop and validate improved pain scales that utilize neuroimaging and 
neurophysiologic techniques [23]. Ultimately, the results from the studies reported in this 
dissertation will prove most useful when linked to high-quality pharmacodynamic data. 
In summary, this dissertation research has elucidated the factors influencing 
acetaminophen disposition in neonates. At present, findings based on the 
pharmacokinetics of both parent drug and hepatotoxicity-associated metabolites support 
cautious implementation of a 20-mg/kg loading dose followed by 10-mg/kg maintenance 
doses every 6 h for administration of intravenous acetaminophen to neonates ranging 
from 27–44 weeks’ postmenstrual age. Future studies should focus on establishing 
appropriate pharmacodynamic targets and identifying patient characteristics that can be 
used to further reduce the amount of unpredictable variability in the pharmacokinetics of 
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